Patent Application
20170073415
The present invention relates to novel multispecific molecules, particularly bispecific molecules, and novel methods of treatment based on such multispecific molecules, wherein the multispecific molecules comprise an antibody, or a functional fragment thereof, with high affinity combined with high potency, particularly an antibody, or a functional fragment thereof, against a particular epitope.
This invention relates to novel multispecific molecules, particularly bispecific molecules, comprising an anti-CD3 antibody, or a functional fragment thereof, wherein the anti-CD3 antibody, or a functional fragment thereof, combines high affinity with high potency, and wherein in particular the anti-CD3 antibody, or a functional fragment thereof, specifically recognizes a particular CD3 epitope.
The T cell receptor or TCR is a molecule found on the surface of T lymphocytes (or T cells) that is responsible for recognizing antigens bound to major histocompatibility complex (MHC) molecules on the surface of antigen presenting cells (APC). The binding between TCR and antigen is of relatively low affinity. When the TCR engages with antigen and MHC, the T lymphocyte is activated through a series of biochemical events mediated by associated enzymes, co-receptors, specialized accessory molecules, and activated or released transcription factors.
The TCR is associated with other molecules like CD3, which possess three distinct chains (γ, δ, and ε) in mammals, and either a ζ2 (CD247) complex or a ζ/η complex. These accessory molecules have transmembrane regions and are vital to propagating the signal from the TCR into the cell; the cytoplasmic tail of the TCR is extremely short, making it unlikely to participate in signaling. The CD3- and ζ-chains, together with the TCR, form what is known as the T cell receptor complex.
CD3ε is a type I transmembrane protein expressed on the surface of certain T cells. It participates in the T cell receptor (TCR) complex and interacts with other domains of this complex. One of these interaction partners is CD3γ, which binds to CD3ε in a 1:1 stoichiometry (De la Hera et al, J. Exp. Med. 1991; 173: 7-17).
It is well established that peptide-MHC complexes bind TCR with low affinity and fast off rate (Matsui et al, Science. 1991; 254: 1788-1791; Weber et al, Nature. 1992; 356: 793-796). It has been suggested that this low affinity is instrumental to allow a few peptide-MHC complexes to serially trigger many TCRs (Valitutti et al, Nature. 1995; 375: 148-151) by repeated binding and dissociation. This serial triggering is critical to sustain signaling over time, allowing T cells to eventually reach the activation threshold (Valitutti et al, Immunol. Today. 1997; 18: 299-304; Lanzavecchia et al, Cell. 1999; 96: 1-4). This notion is supported by the finding that, when compared to peptide-MHC complexes, high-affinity anti-CD3 antibodies do not efficiently stimulate T cells, since they trigger TCR with a 1:1 stoichiometry (Viola et al, Science 1996; 273: 104-106), suggesting that low-affinity antibodies may be more effective in stimulating T cells via TCR signaling because of their ability to repeatedly dissociate and re-bind to CD3ε. Indeed, in a direct comparison of three derivatives of the anti-CD3ε antibody TR66, which all bind with different affinities, wild-type TR66 having an intermediate affinity showed best efficacy in T cell activation when compared to its derivatives that have either higher or lower affinities (Bortoletto et al, J. Immuno. 2002; 32:3102-3107). Thus, a KD at around that of TR66 is ideal for the stimulation of T cells. The affinity of TR66 has been determined by use of surface-plasmon resonance (SPR) technology as well as by flow-cytometry, yielding equilibrium dissociation constants of 2.6×10−7 M (Moore et al, Blood. 2011; 117: 4542-4551) and 1.0×10−7 M (Amann et al, Cancer Res. 2008; 68: 143-151), respectively. In line with this, it has been recommended to use anti-CD3 antibodies with an affinity of less than 10−8 M (U.S. Pat. No. 7,112,324), and the T cell-stimulatory antibodies that have been published for human therapeutic use, bind with affinities to human CD3ε in the same range. Therefore, according to the theory of serial TCR triggering and in agreement with published results for anti-CD3ε antibodies, monoclonal antibodies with affinities significantly better than the ones published are not expected to be more potent stimulators of T cells but in contrast are expected to be weaker activators.
Some of the published antibodies against CD3ε have been generated via immunization of animals with T cell preparations and subsequent isolation of monoclonal antibodies by the so-called hybridoma procedure. The weakness of this approach is that the unselective immune response against various antigens of foreign (human) T cells in the animal, on one hand, and the poor efficiency of the hybridoma procedure on the other hand, decrease the probability to identify monoclonal antibodies with T cell-stimulatory activity, also because these agonistic antibodies may represent a minority in the entirety of anti-CD3ε antibodies. Immunization with a linear peptide spanning the targeted epitope increases the selectivity of the immune response, may, however, result in antibodies that do not recognize the native full-length CD3ε or that may exert non-optimal TCR stimulation.
For the immunization of animals with other type-I transmembrane proteins it has been particularly useful to use the purified extracellular domain (ECD). However, purified ECD of CD3ε tends to aggregate, and aggregates may have an altered structure as compared to the native protein. Further this approach may preferentially lead to antibodies binding to the interface between CD3ε and CD3γ. In contrast, the complex of CD3ε and CD3γ produced as a single-chain protein, connected by a flexible peptide linker, can be purified in a monomeric fraction and in its native conformation (Kim et al, JMB. 2000; 302: 899-916). Immunization of animals with such a CD3ε/γ single-chain protein may however lead to antibodies concomitantly binding to CD3ε and CD3γ, which would result in antagonistic effects.
Several antibodies directed against human CD3ε have been developed in the past.
Monoclonal antibody SP34 is a murine antibody that cross-reacts with non-human primate CD3, and that is also capable of inducing cell proliferation on both human and non-human primate PBMCs (Pessano et al., The T3/T cell receptor complex: antigenic distinction between the two 20-kD T3 (T3δ and T3ε) subunits. EMBO J 4 (1985) 337-344).
WO 2007/042261 and WO 2008/119567, both assigned to Micromet, disclose cross-reactive binders directed against the epitopes FSEXE and QDGNE, respectively, in CD3ε. In opposition proceedings filed by several opponents against granted European patent EP 2 155 783 (based on the regional phase of WO 2008/119567), it is submitted that SP34 is binding to epitope QDGNE as well.
However, despite the fact that many attempts have been made to address the issue of obtaining anti-CD3 antibodies, or to binding molecules in general, with particularly advantageous properties, so far these attempts had limited success.
Thus, there remained still a large unmet need to develop novel CD3 binding molecules, in particular novel anti-CD3 antibodies, for high affinity, which is not limiting for high potency. Additionally, there remained still a large unmet need to develop novel CD3 binding molecules, in particular novel anti-CD3 antibodies, for high affinity, which are cross-reactive with other species, in particular with non-human primates such as cynomolgus monkeys.
The solution for this problem is provided by the CD3-binding molecules, in particular anti-CD3 antibodies shown in the present application, in particular the examples. These antibodies can be obtained by genetic immunization of rabbits and screening of affinity matured memory B-cells, and can be shown to have specificity for a novel agonistic epitope on CD3ε, which had not been achieved or suggested by the prior art before.
A promising approach for the antibody-based treatment of various malignancies as well as potentially for the treatment of infectious and autoimmune diseases is the redirection of immune effector cells to specifically lyse target cells using bispecific antibodies. The bispecific antibodies recognize a particular antigen on the surface of a target cell and, simultaneously, an activating surface molecule of an immune effector cell, such as a natural killer (NK) cell or a cytotoxic T (Tc) cell, to thereby kill the target cells.
The bispecific antibody concept is, for example, used in cancer therapy where bispecific antibodies are employed that bind to a cancer antigen on cancer cells and, simultaneously, to the epsilon chain of CD3 presented on, for example, cytotoxic T cells. A well-known example of such a bispecific antibody construct is “blinatumomab”, an antibody in the BiTE (bi-specific T cell engager) format, for the treatment of non-Hodgkin's lymphoma and acute lymphoblastic leukemia. Blinatumomab was developed by Micromet and simultaneously binds to the cancer antigen CD19 as well as to CD3 on the surface of cytotoxic T cells, thereby linking these two cell types together and activating the cytotoxic T cell to lyse the target cancer cell. The CD3 binding domain of Blinatumomab is derived from the anti-CD3ε antibody TR66.
T cells activated by Blinatumomab not only produce cytolytic factors, such as granzyme B and perforin that are directly involved in the lysis of target cells, but do also produce cytokines, such as interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor alpha (TNFα), Interferon gamma (IFNγ) and Transforming growth factor beta (TGFβ). While pro-inflammatory cytokines (e.g. IL-2, IL-6, TNF and IFNγ) may promote local and systemic inflammation and thereby cause side effects, immune-suppressive factors (e.g. IL-10 and TGFβ) at high concentrations may negatively impact on the cytolytic activity of CD8+ and other CD3+ effector cells.
The majority of patients treated with blinatumomab develop mild inflammatory symptoms related to T-cell activation at initiation of therapy. CRS (cytokine release syndrome) is a more severe condition characterized by “flu-like” symptoms, such as fever, chills, and headache, and the potential for hemodynamic instability, bleeding, capillary leak syndrome, and respiratory compromise. While symptom severity varies, grade 3 or higher CRS has been observed in a small percentage of adult patients (32). Release of inflammatory cytokines IL-2, IL-6, IL-10, INFγ, and TNFα has been demonstrated in adult and pediatric patients (Teachy et al. Blood. 2013; 121:5154-5157; Klinger et al. Blood. 2012; 119:6226-6233). Data from a phase I portion of a pediatric study correlated early elevation and subsequent decline of inflammatory cytokines with clinical symptoms of CRS, most particularly IL-6 and IL-10, and to a lesser degree INFγ (Gore et al., J Clin Oncol. 2013; 31:10007; Zugmaier et al. Blood. 2013; 122 (70)). The most recent adult ALL study failed to associate degree of elevation of inflammatory cytokines to target B-cell frequency in the blood or bone marrow (Klinger et al. Blood. 2012; 119:6226-6233) or to patient outcome (Topp et al., J Clin Oncol. 2011; 29:2493-2498).
To dampen the pro-inflammatory response associated with blinatumomab therapy, current clinical trials mandate co-administration of dexamethasone at the initiation of therapy, which has been shown in cell culture experiments to effectively reduce cytokine concentration without affecting T-cell activation or the cytotoxic potential of blinatumomab against malignant B-cells (Brandi et al., Cancer Immunol Immunother. 2007; 56:1551-1563), suggesting that cytokine levels are not causally linked to the potency. An additional therapeutic option to negate more severe symptoms of CRS is the IL-6 receptor antibody tocilizumab, which recently showed clinical benefit in a pediatric patient with life-threatening CRS (Teachy et al., Blood. 2013; 121:5154-5157). This addition to the therapeutic arsenal offers an additional option for symptom control in patients with very severe CRS that is not sufficiently managed with steroids.
It is well established that peptide-MHC complexes bind TCR with low affinity and fast off rate (Matsui et al, Science. 1991; 254: 1788-1791; Weber et al, Nature. 1992; 356: 793-796). It has been suggested that this low affinity is instrumental to allow a few peptide-MHC complexes to serially trigger many TCRs (Valitutti et al, Nature. 1995; 375: 148-151) by repeated binding and dissociation. This serial triggering is critical to sustain signaling over time, allowing T cells to eventually reach the activation threshold (Valitutti et al, Immunol. Today. 1997; 18: 299-304; Lanzavecchia et al, Cell. 1999; 96: 1-4). This notion is supported by the finding that, when compared to peptide-MHC complexes, high-affinity anti-CD3 antibodies do not efficiently stimulate T cells, since they trigger TCR with a 1:1 stoichiometry (Viola et al, Science 1996; 273: 104-106), suggesting that low-affinity antibodies may be more effective in stimulating T cells via TCR signaling because of their ability to repeatedly dissociate and re-bind to CD3ε. Indeed, in a direct comparison of three derivatives of the anti-CD3ε antibody TR66, which all bind with different affinities, wild-type TR66 having an intermediate affinity showed best efficacy in T cell activation when compared to its derivatives that have either higher or lower affinities (Bortoletto et al, J. Immuno. 2002; 32:3102-3107). Thus, a KD at around that of TR66 is ideal for the stimulation of T cells. The affinity of TR66 has been determined by use of surface-plasmon resonance (SPR) technology as well as by flow-cytometry, yielding equilibrium dissociation constants of 2.6×10−7 M (Moore et al, Blood. 2011; 117: 4542-4551) and 1.0×10−7 M (Amann et al, Cancer Res. 2008; 68: 143-151), respectively. In line with this, it has been recommended to use anti-CD3 antibodies with an affinity of less than 10−8 M (U.S. Pat. No. 7,112,324), and the T cell-stimulatory antibodies that have been published for human therapeutic use, bind with affinities to human CD3ε in the same range. Therefore, according to the theory of serial TCR triggering and in agreement with published results for anti-CD3ε antibodies, monoclonal antibodies with affinities significantly better than the ones published are not expected to be more potent stimulators of T cells but in contrast are expected to be weaker activators.
The solution for this problem that has been provided by the present invention, i.e. bispecific molecules comprising a CD3-binding molecule, in particular an anti-CD3 antibody obtained by genetic immunization of rabbits and screening of affinity matured memory B-cells, and in particular a CD3-binding molecule, in particular an anti-CD3 antibody, with specificity for a novel agonistic epitope, wherein the CD3-binding molecules, particularly the anti-CD3 antibodies exhibit a potency resulting in similar or even more efficient lysis of target cells, while simultaneously resulting in lower production of cytokines, has so far not been achieved or suggested by the prior art.
The present invention relates to novel multispecific molecules based on CD3-binding molecules, in particular antibodies or functional fragments thereof, each comprising a binding region, particularly an antigen-binding region, wherein said binding molecules, in particular said antibodies or functional fragments thereof, are specific for an epitope of human CD3, particularly for a novel agonistic epitope of CD3ε, wherein said binding molecules, in particular said antibodies or functional fragments thereof, have a higher affinity than the prior art antibodies, particularly OKT-3 and/or TR66, while simultaneously exhibiting a potency resulting in similar or even more efficient lysis of target cells, while simultaneously resulting in lower production of cytokines.
Thus, in a first aspect, the present invention relates to a multispecific molecule comprising at least (i) a target-binding moiety; and (ii) a binding molecule comprising a binding region that is specific for an epitope of human CD3ε, wherein said binding region is an antibody or a functional fragment thereof comprising an antigen-binding region comprising a VL domain selected from the group of SEQ ID NOs: 21, 23, and 24, and the VH domain of SEQ ID NO: 22; provided that when said VL domain is of SEQ ID NO: 21, said target binding moiety is not specific for IL5R.
in a second aspect, the present invention relates to a multispecific molecule comprising at least (i) a target-binding moiety; and (ii) a binding molecule that is a binding molecule according to one or more of the following definitions (a) to (g):
In a third aspect, the present invention relates to a multispecific molecule comprising at least (i) a target-binding moiety; and (ii) a binding molecule, which is a binding molecule, particularly an antibody or a functional fragment thereof, binding to essentially the same epitope as the antibody or functional fragment thereof of Sections [0097] to [0099], [00102] to [00104] and [00108].
In a fourth aspect, the present invention relates to a pharmaceutical composition comprising a multispecific molecule of the present invention, in particular a multispecific antibody or a functional multispecific fragment thereof, and optionally a pharmaceutically acceptable carrier and/or excipient.
In a fifth aspect, the present invention relates to a nucleic acid sequence or a collection of nucleic acid sequences encoding a multispecific molecule of the present invention, in particular a multispecific antibody or functional multispecific fragment thereof.
In a sixth aspect, the present invention relates to a vector or a collection of vectors comprising the nucleic acid sequence or a collection of nucleic acid sequences of the present invention.
In a seventh aspect, the present invention relates to a host cell, particularly an expression host cell, comprising the nucleic acid sequence or the collection of nucleic acid sequences of the present invention, or the vector or collection of vectors of the present invention.
In an eighth aspect, the present invention relates to a method for producing a multispecific molecule of the present invention, in particular an multispecific antibody or a functional multispecific fragment thereof, comprising the step of expressing the nucleic acid sequence or the collection of nucleic acid sequences of the present invention, or the vector or collection of vectors of the present invention, or the host cell, particularly an expression host cell, of the present invention.
In a ninth aspect, the present invention relates to a method for generating a multispecific molecule in accordance with the present invention comprising a CD3ε-binding antibody or a functional fragment thereof, comprising the steps of:
In a tenth aspect, the present invention relates to a multispecific molecule of the present invention for use in the treatment of a disease selected from cancer, an inflammatory disease, a metabolic disease, a cardiovascular disease, an autoimmune disease, an infectious disease, a neurologic disease, and a neurodegenerative disease.
In an eleventh aspect, the present invention relates to a method of treating a disease selected from cancer, an inflammatory disease, a metabolic disease, a cardiovascular disease, an autoimmune disease, an infectious disease, a neurologic disease, and a neurodegenerative disease, comprising the step of administering a multispecific molecule of the present invention to a patient in need thereof.
The peculiarity of this invention compared to former bispecific molecules comprising CD3-binding molecules is the fact that the novel multispecific molecules comprise CD3-binding molecules have higher affinities than the prior art antibodies, particularly OKT-3 and/or TR66, while simultaneously exhibiting potencies resulting in similar or even more efficient lysis of target cells, while simultaneously resulting in lower production of cytokines.
An anti-CD3 domain, when incorporated in a multispecific molecule, that would a) result in similar or even more efficient lysis of target cells, and b) result in lower production of cytokines would allow to apply similarly effective doses at better safety or to shift the maximal tolerated dose towards more effective levels. This would be beneficial for the therapy of patients that are particularly sensitive to the cytokines produced upon T cell activation by conventional CD3 binding domains, such as TR66, and would further allow exploiting T cell redirecting therapeutics in non-life-threatening indications. Indications that such results appear to be feasible have recently been provided by the applicants for European patent EP 2 155 783 B1 in a submission dated Oct. 2, 2014, which was filed in the course of opposition proceedings filed against the granted patent at the European Patent Office.
The present application describes a novel humanized CD3 binding antibody variable domain that, when compared to the variable domain of TR66 incorporated into a bispecific scDb antibody fragment, (i) induces more complete lysis of target cells, (ii) shows similar potency of specific target cell lysis, (iii) results in lower production of cytokines produced by CD8+ T cells at maximally effective concentrations, and (iv) shows maintained T cell activity and target cell lysis over a broader range of concentrations.
In particular, a bi- or multi-specific protein retargeting CD3+ T cells to target cells containing the humanized clone 6 as a CD3 binding domain described herein, results in reduced production of IFNγ, TNFα, IL-6, IL-10 and TGFβ at maximally effective concentrations, when compared to a similar protein containing the variable domain of TR66.
Further, a bi- or multi-specific protein retargeting CD3+ T cells to lyse target cells containing the humanized clone 6 as CD3 binding domain described herein, results in reduced expression of factors that are involved in the suppression of T cell activity such as IL-10, TGFβ, PD-1, TIM-3, CTLA-4, CD160, CD244, LAG-3, etc.
Thus, in a first aspect, the present invention relates to a multispecific molecule comprising at least (i) a target-binding moiety; and (ii) a binding molecule comprising a binding region that is specific for an epitope of human CD3ε, wherein said binding region is an antibody or a functional fragment thereof comprising an antigen-binding region comprising a VL domain selected from the group of SEQ ID NOs: 21, 23, and 24, and the VH domain of SEQ ID NO: 22; provided that when said VL domain is of SEQ ID NO: 21, said target binding moiety is not specific for IL5R.
In a particular embodiment, said target moiety is specific for IL23R. In particular embodiments, said target moiety is an antibody or a functional fragment thereof comprising an antigen-binding region comprising a VL domain selected from the group of SEQ ID NOs: 25, 26, and 27, and the VH domain of SEQ ID NO: 28
In a second aspect, the present invention relates to a multispecific molecule comprising at least (i) a target-binding moiety; and (ii) a binding molecule that is a binding molecules according to one or more of the following definitions (a) to (f):
In the context of the present invention, the term “multispecific molecule” refers to a molecule comprising at least two binding specificities, i.e. at least two binding sites, which are specific for a cognate target. The definition of this term thus includes, but is not limited to, bispecific molecules consisting of two binding sites, such as a single-chain diabody (scDb), bispecific molecules comprising two or more copies of at least one binding site, such as a tandem scDb (Tandab); or trispecific molecules consisting of three binding sites, such as a tribody or triabody. In particular embodiments, the multispecific molecule is a bispecific molecule. In other particular embodiments, the multispecific molecule is a trispecific molecule.
In particular embodiments, the target-binding moiety is a binding moiety with binding specificity for a target present on the surface of a cell. In particular embodiments, the target is selected from the group of: 5t4; ANG1; ANG2; ASG-5ME; BCR; BTLA; CCR7; CD1; CD10; CD105; CD126; CD133; CD138; CD14; CD15; CD16; CD174; CD18; CD19; CD2; CD20; CD205; CD21; CD22; CD227; CD23; CD24; CD25; CD27; CD28; CD3; CD30; CD326; CD33; CD340; CD37; CD4; CD44; CD44v3; CD44v6; CD46; CD5; CD52; CD53; CD55; CD56; CD64; CD70; CD72; CD74; CD75; CD77; CD79; CD79a; CD79a/CD79b; CD79b; CD8; CD80; CD81; CD82; CD83; CD84 (SLAM5); CD85; CD86; CD95; CDCP 1 (CD3 18); cMet; CRAC; Cripto; CSPGs; CTLA-4; CXCL12; CXCR4; CXCR7b; DLL1; DLL4; ED-B; EFNa1; EFNa2; EGF receptor (ErbB1); EGFL7; EGFR; EGP-1; EGP-2; EpCam; EphA2; ErbB2 (CD340); ErbB3; ErbB4; Factor H; FAP (fibroblast activation protein); Fc gamma RUB; FGF1; FGF10; FGF18b; FGF19; FGF2; FGF23; FGF4; FGF7; FGF8b; FGFR; FGFR1; FGFR1-IIIC; FGFR2; FGFR2-IIIa; FGFR2-IIIb; FGFR2-IIIc, FGFR3; FGFR4; FHL-1; Flt-3; FOLR1; FZD1; FZD2; FZD4; FZD5; FZD6; FZD7; FZD8; Ga 733; GCSF; GD2; GP130; GPNMB (glycoprotein non-metastatic melanoma protein); GROB; HCG; HER-2/neu; HGF; HIF; HLA-DR (CD74); HM1; HMGB-1; HVEM Ligand; ICOSL (B7-H2); IFN-alpha; IFN-alphaR1; IFN-alphaR2; IFN-beta; IFN-gamma; IFN-gammaR1; IFN-gammaR3; IGF1; IGF1-R; IGF2; IL1; IL1 beta; IL12; IL12p40; IL12RB 1; IL13; IL13R; IL15; IL15R; IL17; IL17R; IL18; IL18R; IL1bcta; IL1R; IL2; IL23; IL25; IL2R; IL4; IL4R; IL6; IL6a receptor (GP 130); IL8; IL9; ILI beta; ILIbeta; insulin-like growth factor (ILGF); IP-10; Jagged; Jagged1; Jagged2; Jagged3; KIT; MAG; MDC; MDX-1342; MEDI-551; mesothelin; MIF; MMP12; MMP2; MMP7; MMP9; MN (carbonic anhydrase IX); MUC 16; NGF; NgR; NKG2D; NogoA; Notch; Notch1; Notch3; Notch4; NotchI, NRP1; OMGp; P1GF; p55; p60; PD-1; PDGFA; PDGFB; PDGFR1; PDGFRA; PDGFRB; PDL1; PED2; PEG2; PGE4; P-glycoprotein (encoded by MDR1); PLAU; PLGF; PSMA; PTPRC; RET; RGM B; ROB04; RON (MST1 R); SGN-19A; SGN-CD19A; SLC44A4; SPRR2a; SPRR2b; TAG-72; TARC; Te38; TGF alpha; TGF beta; TGF1 R; TGFp; TGFPR2; TGFpRI; TIE2; TLR 4; TLR1; TLR2; TLR3; TLR4; TLR5; TLR6; TMEFF2; TNF alpha; TNFRSF 12 (TWEAKR); TNFRSF1 1A (RANK); TNFRSF1 A (TNFR1); TNFRSF10A (DR4); TNFRSF10B (DR5); TNFRSF13B (TACI); TNFRSF13C (BAFFR); TNFRSF14 (HVEM); TNFRSF17 (BCMA); TNFRSF18 (GITR); TNFRSF19 (TROY); TNFRSF19L (RELT); TNFRSF1B (TNFR2); TNFRSF21 (DR6); TNFRSF25 (DR3); TNFRSF3 (LTBR); TNFRSF4 (OX40); TNFRSF5 (CD40); TNFRSF6 (Fas; TNFRSF6B (DcR3); TNFRSF7 (CD27); TNFRSF8 (CD30); TNFRSF9 (4 IBB); TNFRSFIOA (DR4); TNFSF1 (TNFb; TNFSF1 1 (RAN L); TNFSF1 1 (RANKL); TNFSF12 (TWEAK); TNFSF13 (APRIL); TNFSF13B (BLYS); TNFSF14 (LIGHT; TNFSF15 (TL1A); TNFSF18 (GITR Ligand); TNFSF3 (LTb); TNFSF4 (OX40 Ligand); TNFSF5 (CD40 Ligand); TNFSF6 (Fas Ligand); TNFSF7 (CD27 Ligand; TNFSF8 (CD30 Ligand); TNFSF9 (4 IBB Ligand); VCAM1; VEGF; VEGFA; VEGFB; VEGFR1; VEGFR2; VEGFR3; WNT A; WNT I 6; WNT1 1; WNT2; WNT2b; WNT3; WNT3A; WNT4; WNT5B; WNT6; WNT7A; WNT7B; WNT8A; WNT8B; WNT9A; WNT9B; WNTI. In more particular embodiments, the target is selected from the group of: Interleukin-23 receptor (IL23R) IL12R-beta 1, IL12R beta 2, CCR6, CCR4, CXCR4, HER1, HER2, and HER3. In particular embodiments, the target is not IL5R.
In particular embodiments, the binding molecule is a binding molecule comprising a binding region that is specific for an epitope of human CD3ε, in particular an antibody or a functional fragment thereof comprising an antigen-binding region, wherein said epitope comprises amino acid residue N4 as residue that is critical for binding.
In the context of the present invention, an amino acid residue is to be considered “critical for binding”, when the binding affinity of a binding molecule to a peptide comprising said amino acid residue position is reduced to at least 50%, particularly to at least 25%, more particularly to at least 10%, and most particularly to at least 5% of the binding affinity to the wild-type peptide sequence, when said critical amino acid residue is exchanged by alanine. and/or when the average signal intensity resulting from binding to a peptide comprising said amino acid residue position as determined by the ELISA of Example 7 is reduced to at least 50%, particularly to at least 25%, and most particularly to at least 10% of the binding signal to the wild-type peptide sequence, when said critical amino acid residue is separately exchanged by each of the other natural amino acid residues except cysteine.
In particular embodiments, said epitope further comprises amino acid residue E6 as residue that is involved in binding. In particular embodiments, said epitope further comprises amino acid residue E6 as residue that is critical for binding.
In the context of the present invention, an amino acid residue is to be considered “involved in binding”, when the binding affinity of a binding molecule is reduced to at least 80%, when said amino acid residue is exchanged by alanine, and/or when the average signal intensity resulting from binding to a peptide comprising said amino acid residue position as determined by the ELISA of Example 7 is reduced to at least 80%, when said amino acid residue is separately exchanged by each of the other natural amino acid residues except cysteine.
In particular embodiments, at least one of residues Q1, D2, G3 and E5 of CD3e is non-critical for binding. In particular embodiments, at least two of residues Q1, D2, G3 and E5 of CD3e is non-critical for binding, more particularly at least three, and most particularly all four residues Q1, D2, G3 and E5 of CD3e are non-critical for binding.
In the context of the present invention, an amino acid residue is to be considered “non-critical for binding”, when the binding affinity of a binding molecule to a peptide comprising said amino acid residue position is reduced to not less 80%, more particularly to not less than 90%, and most particularly to not less than 95% of the binding affinity to the wild-type peptide sequence, when said non-critical amino acid residue is exchanged by alanine. and/or when the average signal intensity resulting from binding to a peptide comprising said amino acid residue position as determined by the ELISA of Example 7 is reduced to not less than 50%, particularly to not less than 70%, more particularly to not less than 80%, and most particularly to not less than 90% of the binding signal to the wild-type peptide sequence, when said non-critical amino acid residue is separately exchanged by each of the other natural amino acid residues except cysteine.
In particular embodiments, said binding molecule is an antibody or a functional fragment thereof.
In particular embodiments, said binding molecule, particularly said antibody or functional fragment thereof, is cross-reactive with cynomolgus CD3, particularly cynomolgus CD3ε, particularly having an affinity to cynomolgus monkey CD3ε that is less than 100-fold, particularly less than 30-fold, even more particularly less than 15-fold and most particularly less than 5-fold different to that of human CD3ε.
In particular embodiments, said binding molecule, in particular said antibody or functional fragment thereof, is binding to human CD3 with an equilibrium dissociation constant for monovalent binding of less than 3.0×10−8 M, particularly less than 1.5×10−8 M, more particularly less than 1.2×10−8 M, and most particularly less than 1.0×10−8 M.
In particular embodiments, said binding molecule is an antibody or a functional fragment thereof, which, when tested in an IgG format, upon cross-linking, is inducing T-cell activation at least 1.5-fold stronger than antibodies OKT-3 or TR66 after 24 h of stimulation at an IgG concentration of 1.25 μg/ml.
In particular embodiments, said binding molecule is an antibody or a functional fragment thereof, which, when tested in an IgG format upon cross-linking, is resulting in T-cell activation, which lasts longer than with antibodies OKT-3 or TR66 as indicated by at least 1.5-fold greater increase in CD69 expression after 72 hours of stimulation at an IgG concentration of 1.25 μg/ml.
In particular embodiments, said binding molecule is an antibody or a functional fragment thereof, which, when tested in an IgG format, upon cross-linking, is resulting in a dose-dependent activation state of T-cells that is less heterogeneous when compared to activation by OKT-3 or TR66.
In particular embodiments, the binding molecule is a CD3-binding molecule that is specific for an epitope of human CD3, wherein said CD3-binding molecule is binding to human CD3 with a dissociation constant for monovalent binding of less than 3.0×10−8 M, particularly less than 1.5×10−8 M, more particularly less than 1.2×10−8 M, and most particularly less than 1.0×10−8 M, in particular to an antibody or a functional fragment thereof comprising an antigen-binding region that is specific for an epitope of human CD3, wherein said antibody or functional fragment thereof, is binding to human CD3 with a dissociation constant for monovalent binding of less than 3.0×10−8 M, particularly less than 1.5×10−8 M, more particularly less than 1.2×10−8 M, and most particularly less than 1.0×10−8 M.
In particular embodiments, said binding molecule, particularly said antibody or functional fragment thereof, is cross-reactive with cynomolgus CD3, particularly cynomolgus CD3ε, particularly having an affinity to cynomolgus monkey CD3ε that is less than 100-fold, particularly less than 30-fold, even more particularly less than 15-fold and most particularly less than 5-fold different to that of human CD3ε.
In particular embodiments, the binding molecule is an antibody or a functional fragment thereof comprising an antigen-binding region that is specific for an epitope of human CD3, wherein said antibody or functional fragment thereof, when tested in an IgG format, upon cross-linking, is inducing T-cell activation at least 1.5-fold stronger than antibodies OKT-3 or TR66 after 24 h of stimulation at an IgG concentration of 1.25 μg/ml.
In particular embodiments, said binding molecule, particularly said antibody or functional fragment thereof, is cross-reactive with cynomolgus CD3, particularly cynomolgus CD3ε, particularly having an affinity to cynomolgus monkey CD3ε that is less than 100-fold, particularly less than 30-fold, even more particularly less than 15-fold and most particularly less than 5-fold different to that of human CD3ε.
In particular embodiments, the binding molecule is an antibody or a functional fragment thereof comprising an antigen-binding region that is specific for an epitope of human CD3, wherein said antibody or functional fragment thereof, when tested in an IgG format upon cross-linking, is resulting in T-cell activation, which lasts longer than with antibodies OKT-3 or TR66 as indicated by at least 1.5-fold greater increase in CD69 expression after 72 hours of stimulation at an IgG concentration of 1.25 μg/ml.
In particular embodiments, said binding molecule, particularly said antibody or functional fragment thereof, is cross-reactive with cynomolgus CD3, particularly cynomolgus CD3ε, particularly having an affinity to cynomolgus monkey CD3ε that is less than 100-fold, particularly less than 30-fold, even more particularly less than 15-fold and most particularly less than 5-fold different to that of human CD3ε.
In particular embodiments, the binding molecule is an antibody or a functional fragment thereof comprising an antigen-binding region that is specific for an epitope of human CD3, wherein said antibody or functional fragment thereof, when tested in an IgG format, upon cross-linking, is resulting in a dose-dependent homogeneous activation state of T-cells.
In particular embodiments, said binding molecule, particularly said antibody or functional fragment thereof, is cross-reactive with cynomolgus CD3, particularly cynomolgus CD3ε, particularly having an affinity to cynomolgus monkey CD3ε that is less than 100-fold, particularly less than 30-fold, even more particularly less than 15-fold and most particularly less than 5-fold different to that of human CD3ε.
In particular embodiments, the binding molecule is an antibody or a functional fragment thereof comprising an antigen-binding region that is specific for an epitope of human CD3, wherein said antibody or functional fragment thereof, when tested in an IgG format, (i) is binding to human CD3 with a dissociation constant for monovalent binding of less than 3.0×10−8 M, particularly less than 1.5×10−8 M, more particularly less than 1.2×10−8 M, and most particularly less than 1.0×10−8 M; and (iia), upon cross-linking, is inducing T-cell activation at least 1.5-fold stronger than antibodies OKT-3 or TR66 after 24 h of stimulation at an IgG concentration of 1.25 μg/ml; (iib) is resulting in T-cell activation, which lasts longer than with antibodies OKT-3 or TR66 as indicated by at least 1.5-fold greater increase in CD69 expression after 72 hours of stimulation at an IgG concentration of 1.25 μg/ml; (iic) is resulting in a dose-dependent homogeneous activation state of T-cells; and/or (iid) is specific for an epitope of human CD3ε, wherein said epitope comprises amino acid residue N4 as residue that is critical for binding.
In particular embodiments, the binding molecule is an antibody or a functional fragment thereof comprising an antigen-binding region that is specific for an epitope of human CD3, wherein said multispecific molecule exhibits a potency resulting in similar or even more efficient lysis of target cells when compared to a multispecific construct comprising TR66 as CD3-binding moiety in the same format as said multispecific molecule, while simultaneously resulting in lower production of cytokines.
In the context of the present invention, the term “potency” refers to a combination of the ED50 concentration and the degree of cell lysis. Furthermore, in the context of the present invention the term “lower production of cytokines” refers to the fact that the level of cytokines in the medium, measured at the lowest concentration of the multispecific molecule of this invention that results in maximal lysis of target cells, using a method well known to the expert (e.g. ELISA), is 10%, preferably 20%, more preferably 35% and most preferably 50% lower as compared to the same multispecific molecule containing TR66 as CD3-binding domain.
In particular such embodiments, said antibody or functional fragment thereof, is additionally cross-reactive with cynomolgus CD3, particularly cynomolgus CD3ε, particularly having an affinity to cynomolgus monkey CD3ε that is less than 100-fold, particularly less than 30-fold, even more particularly less than 15-fold and most particularly less than 5-fold different to that of human CD3ε.
In the context of the present invention, the term “antibody” is used as a synonym for “immunoglobulin” (Ig), which is defined as a protein belonging to the class IgG, IgM, IgB, IgA, or IgD (or any subclass thereof), and includes all conventionally known antibodies and functional fragments thereof. A “functional fragment” of an antibody/immunoglobulin is defined as a fragment of an antibody/immunoglobulin (e.g., a variable region of an IgG) that retains the antigen-binding region. An “antigen-binding region” of an antibody typically is found in one or more hypervariable region(s) of an antibody, i.e., the CDR-1, -2, and/or -3 regions; however, the variable “framework” regions can also play an important role in antigen binding, such as by providing a scaffold for the CDRs. Preferably, the “antigen-binding region” comprises at least amino acid residues 4 to 103 of the variable light (VL) chain and 5 to 109 of the variable heavy (VH) chain, more preferably amino acid residues 3 to 107 of VL and 4 to 111 of VH, and particularly preferred are the complete VL and VH chains (amino acid positions 1 to 109 of VL and Ito 113 of VH; numbering according to WO 97/08320). In the case of rabbit antibodies, the CDR regions are indicated in Table 5 (see below). A preferred class of immunoglobulins for use in the present invention is IgG. “Functional fragments” of the invention include the domain of a F(ab′)2 fragment, a Fab fragment and scFv. The F(ab′)2 or Fab may be engineered to minimize or completely remove the intermolecular disulphide interactions that occur between the CH1 and CL domains.
As used herein, a binding molecule is “specific to/for”, “specifically recognizes”, or “specifically binds to” a target, such as human CD3 (or an epitope of human CD3), when such binding molecule is able to discriminate between such target biomolecule and one or more reference molecule(s), since binding specificity is not an absolute, but a relative property. In its most general form (and when no defined reference is mentioned), “specific binding” is referring to the ability of the binding molecule to discriminate between the target biomolecule of interest and an unrelated biomolecule, as determined, for example, in accordance with a specificity assay methods known in the art. Such methods comprise, but are not limited to Western blots, ELISA, RIA, ECL, IRMA tests and peptide scans. For example, a standard ELISA assay can be carried out. The scoring may be carried out by standard colour development (e.g. secondary antibody with horseradish peroxide and tetramethyl benzidine with hydrogen peroxide). The reaction in certain wells is scored by the optical density, for example, at 450 nm. Typical background (=negative reaction) may be about 0.1 OD; typical positive reaction may be about 1 OD. This means the ratio between a positive and a negative score can be 10-fold or higher. Typically, determination of binding specificity is performed by using not a single reference biomolecule, but a set of about three to five unrelated biomolecules, such as milk powder, BSA, transferrin or the like. In particular embodiments, determination of binding specificity is performed by using the set of milk powder, BSA, and transferrin as reference.
In the context of the present invention, the term “about” or “approximately” means between 90% and 110% of a given value or range.
However, “specific binding” also may refer to the ability of a binding molecule to discriminate between the target biomolecule and one or more closely related biomolecule(s), which are used as reference points. Additionally, “specific binding” may relate to the ability of a binding molecule to discriminate between different parts of its target antigen, e.g. different domains, regions or epitopes of the target biomolecule, or between one or more key amino acid residues or stretches of amino acid residues of the target biomolecule. Thus, in particular embodiments, specific binding to a particular epitope on a human target does not exclude, or even mandates, binding to non-human targets in a situation, where the non-human target comprises the identical, or at least very similar, epitope.
In the context of the present invention, the term “epitope” refers to that part of a given target biomolecule that is required for specific binding between the target biomolecule and a binding molecule. An epitope may be continuous, i.e. formed by adjacent structural elements present in the target biomolecule, or discontinuous, i.e. formed by structural elements that are at different positions in the primary sequence of the target biomolecule, such as in the amino acid sequence of a protein as target, but in close proximity in the three-dimensional structure, which the target biomolecule adopts, such as in the bodily fluid.
In one embodiment, the epitope is located on the epsilon chain of human CD3.
In certain embodiments, said binding to human CD3ε is determined by determining the affinity of said antibody or functional fragment thereof in an IgG format to the purified extracellular domain of heterodimeric CD3εγ of human origin using a surface plasmon resonance experiment.
In a particular embodiment, the following conditions are used, as shown in Example 1: MASS-1 SPR instrument (Sierra Sensors); capture antibody: antibody specific for the Fc region of said IgG immobilized on an SPR-2 Affinity Sensor chip, Amine, Sierra Sensors, using a standard amine-coupling procedure; two-fold serial dilutions of human heterodimeric single-chain CD3εγ extracellular domain ranging from 90 to 2.81 nM, injection into the flow cells for 3 min and dissociation of the protein from the IgG captured on the sensor chip for 5 min, surface regeneration after each injection cycle with two injections of 10 mM glycine-HCl, calculation of the apparent dissociation (kd) and association (ka) rate constants and the apparent dissociation equilibrium constant (KD) with the MASS-1 analysis software (Analyzer, Sierra Sensors) using one-to-one Langmuir binding model.
In particular embodiments, said inducing of T-cell activation according to (iia) and/or (iic) is determined by determining the stimulation of CD69 expression by said antibody or functional fragment thereof in an IgG format.
In a particular embodiment, the following conditions are used, as shown in Example 3: stimulation of Jurkat cells (100,000 cells/well) for 24 h with 20 μg/ml, 5 μg/ml and 1.25 μg/ml of said antibody or functional fragment thereof in an IgG format after prior cross-linking by addition of 3-fold excess of an anti-IgG antibody (control: OKT3 (BioLegend, Cat. No. 317302) or TR66 (Novus Biologicals, Cat. No. NBP1-97446), cross-linking with rabbit anti-mouse IgG antibody (JacksonImmuno Research, Cat. No. 315-005-008)); cell staining for CD69 expression after stimulation using a Phycoerithrin (PE)-labeled antibody specific for human CD69 (BioLegend, Cat. No. 310906), analysis with a flow cytometer (FACS aria III, Becton Dickinson); negative control: unstimulated Jurkat cells incubated with the cross-linking antibody stained with said anti-CD69 antibody.
In particular embodiments, said longer lasting T-cell activation according to (iib) is determined by determining the time course of stimulation of CD69 expression by said antibody or functional fragment thereof in an IgG format.
In a particular embodiment, the following conditions are used, as shown in Example 3: stimulation of 100,000 Jurkat cells/well for 0 h, 4 h, 15 h, 24 h, 48 h and 72 h with 5 μg/ml of said antibody or functional fragment thereof in an IgG format anti-CD3 antibodies that have been cross-linked as in [0090] and analysis of CD69 expression by flow cytometry as in [0090].
In particular embodiments, said inducing of T-cell activation according to (iia) and/or (iic) is determined by determining the stimulation of IL-2 secretion by said antibody or functional fragment thereof in an IgG format.
In a particular embodiment, the following conditions are used, as shown in Example 4: stimulation of Jurkat cells (200,000 cells/well) with said antibody or functional fragment thereof in an IgG format at a concentration of 5 μg/ml using 4 different assay setups: (a) stimulation of Jurkat cells with said antibody or functional fragment thereof in an IgG format cross-linked by addition of 3-fold higher concentrations of an anti IgG antibody (control: OKT3 (BioLegend, Cat. No. 317302) or TR66 (Novus Biologicals, Cat. No. NBP1-97446), cross-linking with rabbit anti-mouse IgG antibody (JacksonImmuno Research, Cat. No. 315-005-008)); (b) T-cell activation in absence of cross-linking antibody; (c) immobilization of said cross-linking antibodies on the tissue culture plates by over-night incubation; (d) immobilization of said antibody or functional fragment thereof in an IgG format (or of control antibodies) on the tissue culture plate by over-night incubation in absence of cross-linking antibodies; in each setup, one hour after addition, stimulation of cells with 10 ng/ml PMA and collection of supernatant after 24, 48 and 72 h to measure IL-2 release, quantified using a commercially available ELISA (BioLegend, Cat. No. 431801).
In particular embodiments, the antibody or functional fragment thereof is (i) a rabbit antibody or a functional fragment thereof, or (ii) an antibody or a functional fragment thereof obtained by humanizing the rabbit antibody or functional fragment thereof of (i).
Methods for the humanization of rabbit antibodies are well known to anyone of ordinary skill in the art (see, for example, Borras et al., J Biol Chem. 2010 Mar. 19; 285(12):9054-66; Rader et al, The FASEB Journal, express article 10.1096/fj.02-0281fje, published online Oct. 18, 2002; Yu et al (2010) A Humanized Anti-VEGF Rabbit Monoclonal Antibody Inhibits Angiogenesis and Blocks Tumor Growth in Xenograft Models. PLoS ONE 5(2): e9072. doi:10.1371/journal.pone.0009072).
In particular embodiments, said antibody or functional fragment thereof comprises an antigen-binding region comprising a VH domain comprising a combination of one CDR1, one CDR2 and one CDR3 region present in SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20, particularly SEQ ID NOs: 4, 6, and 10, more particularly SEQ ID NO: 10, particularly wherein said VH domain comprises framework domains selected from the framework domains present in SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20, particularly SEQ ID NOs: 4, 6, and 10, more particularly SEQ ID NO: 10, and a VL domain comprising a combination of one CDR1, one CDR2 and one CDR3 region present in SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, and 19, particularly SEQ ID NOs: 3, 5, and 9, more particularly SEQ ID NO: 9, particularly wherein said VL domain comprises framework domains selected from the framework domains present in SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, and 19, particularly SEQ ID NOs: 3, 5, and 9, more particularly SEQ ID NO: 9. In particular embodiments, the VL domain comprises framework domains selected from the framework domains present in SEQ ID NOs: 21, 23; and 24; and the VH domain comprises framework domains selected from the framework domains present in SEQ ID NO: 22. In other particular embodiments, the VL domain comprises framework domains that are variants of the framework domains present in SEQ ID NOs: 21, 23; and 24; and/or the VH domain comprises framework domains that are variants of the framework domains present in SEQ ID NO: 22, particularly variants comprising one or more non-human donor amino acid residues, particularly donor amino acid residues present in one of the sequences selected from SEQ ID NOs: 1 to 20, instead of the corresponding human acceptor amino residues present in SEQ ID NOs: 21, 23, 24, and/or 22.
In particular embodiments, said antibody or functional fragment thereof comprises an antigen-binding region comprising a VH domain comprising the combination of CDR1, CDR2 and CDR3 present in one of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20, particularly SEQ ID NOs: 4, 6, and 10, more particularly SEQ ID NO: 10, particularly wherein said VH domain comprises the combination of framework domains present in one of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20, particularly SEQ ID NOs: 4, 6, and 10, more particularly SEQ ID NO: 10, and a VL domain comprising the combination of CDR1, CDR2 and CDR3 present in one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, and 19, particularly SEQ ID NOs: 3, 5, and 9, more particularly SEQ ID NO: 9, particularly wherein said VL domain comprises the combination of framework domains present in one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, and 19, particularly SEQ ID NOs: 3, 5, and 9, more particularly SEQ ID NO: 9. In particular embodiments, the VL domain comprises framework domains selected from the framework domains present in SEQ ID NOs: 21, 23; and 24; and the VH domain comprises framework domains selected from the framework domains present in SEQ ID NO: 22. In other particular embodiments, the VL domain comprises framework domains that are variants of the framework domains present in SEQ ID NOs: 21, 23; and 24; and/or the VH domain comprises framework domains that are variants of the framework domains present in SEQ ID NO: 22, particularly variants comprising one or more non-human donor amino acid residues, particularly donor amino acid residues present in one of the sequences selected from SEQ ID NOs: 1 to 20, instead of the corresponding human acceptor amino residues present in SEQ ID NOs: 21, 23, 24, and/or 22.
In particular embodiments, said antibody or functional fragment thereof comprises an antigen-binding region comprising a VH domain selected from SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20, particularly SEQ ID NOs: 4, 6, and 10, more particularly SEQ ID NO: 10, and a VL domain selected from SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, and 19, particularly SEQ ID NOs: 3, 5, and 9, more particularly SEQ ID NO: 9. In other particular embodiments, the VH domain is a variant of a VH domain selected from SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20, particularly SEQ ID NOs: 4, 6, and 10, more particularly SEQ ID NO: 10, and/or the VL domain is a variant of a VL domain selected from SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, and 19, particularly SEQ ID NOs: 3, 5, and 9, more particularly SEQ ID NO: 9, particularly a variant comprising one or more amino acid residue exchanges in the framework domains and/or in CDR residues not involved in antigen binding.
Methods for the identification of amino acid residues in framework regions suitable for exchange, e.g. by homologous amino acid residues, are well known to one of ordinary skill in the art, including, for example, analysis of groups of homologous sequences for the presence of highly conserved residues (which are particularly kept constant) and variegated sequence positions (which may be modified, particularly by one of the residues naturally found at that position).
Methods for the identification of an amino acid residues in the CDR regions suitable for exchange, e.g. by homologous amino acid residues, are well known to one of ordinary skill in the art, including, for example, analysis of structures of antibody binding domains, particularly of structures of antibody binding domains in a complex with antigens for the presence of antigen-interacting residues (which are particularly kept constant) and sequence positions not in contact with the antigen (which may be modified).
In particular other embodiments, said antibody or functional fragment thereof comprises an antigen-binding region comprising a VH domain selected from SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22, particularly SEQ ID NOs: 4, 6, 10, and 22, more particularly SEQ ID NO: 10, and 22, and a VL domain selected from SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 24, particularly SEQ ID NOs: 3, 5, 9, 21, 23, and 24, more particularly SEQ ID NOs: 9, 21, 23, and 24. In other particular embodiments, the VH domain is a variant of a VH domain selected from SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22, particularly SEQ ID NOs: 4, 6, 10, and 22, more particularly SEQ ID NO: 10 and 22, and/or the VL domain is a variant of a VL domain selected from SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 24, particularly SEQ ID NOs: 3, 5, 9, 21, 23, and 24, more particularly SEQ ID NOs: 9, 21, 23, and 24, particularly a variant comprising one or more amino acid residue exchanges in the framework domains and/or in CDR residues not involved in antigen binding.
In particular embodiments, said antibody or functional fragment thereof comprises an antigen-binding region comprising a VH/VL domain combination selected from SEQ ID NO: 1/SEQ ID NO: 2; SEQ ID NO: 3/SEQ ID NO: 4; SEQ ID NO: 5/SEQ ID NO: 6; SEQ ID NO: 7/SEQ ID NO: 8, SEQ ID NO: 9/SEQ ID NO: 10, SEQ ID NO: 11/SEQ ID NO: 12, SEQ ID NO: 13/SEQ ID NO: 14, SEQ ID NO: 15/SEQ ID NO: 16, SEQ ID NO: 17/SEQ ID NO: 18, and SEQ ID NO: 19/SEQ ID NO: 20, particularly SEQ ID NO: 3/SEQ ID NO: 4; SEQ ID NO: 5/SEQ ID NO: 6; and SEQ ID NO: 9/SEQ ID NO: 10, more particularly SEQ ID NO: 9/SEQ ID NO: 10. In particular other embodiments, said antibody or functional fragment thereof comprises an antigen-binding region comprising a variant of a VH/VL domain combination selected from SEQ ID NO: 1/SEQ ID NO: 2; SEQ ID NO: 3/SEQ ID NO: 4; SEQ ID NO: 5/SEQ ID NO: 6; SEQ ID NO: 7/SEQ ID NO: 8, SEQ ID NO: 9/SEQ ID NO: 10, SEQ ID NO: 11/SEQ ID NO: 12, SEQ ID NO: 13/SEQ ID NO: 14, SEQ ID NO: 15/SEQ ID NO: 16, SEQ ID NO: 17/SEQ ID NO: 18, and SEQ ID NO: 19/SEQ ID NO: 20, particularly SEQ ID NO: 3/SEQ ID NO: 4; SEQ ID NO: 5/SEQ ID NO: 6; and SEQ ID NO: 9/SEQ ID NO: 10, more particularly SEQ ID NO: 9/SEQ ID NO: 10, wherein in such variant at least the VL or the VH domain is a variant of one of the VL/VH domains listed.
In a particular embodiment, said antibody or functional fragment thereof comprises an antigen-binding region comprising a VH/VL domain combination selected from SEQ ID NO: 21/SEQ ID NO: 22, SEQ ID NO: 23/SEQ ID NO: 22, and SEQ ID NO: 24/SEQ ID NO: 22. In another embodiment, said antibody or functional fragment thereof comprises a variant of the antigen-binding region comprising a VH/VL domain combination selected from SEQ ID NO: 21/SEQ ID NO: 22, SEQ ID NO: 23/SEQ ID NO: 22, and SEQ ID NO: 24/SEQ ID NO: 22, wherein in such variant at least the VL or the VH domain is a variant of one of the VL/VH domains listed.
In particular embodiments, said antibody or functional fragment thereof comprises an antigen-binding region that is a variant of the sequences disclosed herein. Accordingly, the invention includes an antibody or a functional fragment thereof having one or more of the properties of the antibody or functional fragment thereof comprising SEQ ID NOs: 1 to 20, particularly the properties defined in Sections [0057], [0059], [0061], [0064] to [0069], [0077] and [0078], comprising a heavy chain amino acid sequence with: at least 60 percent sequence identity in the CDR regions with the CDR regions comprised in SEQ ID NO: 2, 4, 6, 8; 10, 12, 14, 16, 18, or 20, particularly SEQ ID NOs: 4, 6, and 10, more particularly SEQ ID NO: 10, particularly at least 70 percent sequence identity, more particularly at least 80 percent sequence identity, and most particularly at least 90 percent sequence identity, and/or at least 80 percent sequence homology, more particularly at least 90 percent sequence homology, most particularly at least 95 percent sequence homology in the CDR regions with the CDR regions comprised in SEQ ID NO: 2, 4, 6, 8; 10, 12, 14, 16, 18, or 20, particularly SEQ ID NOs: 4, 6, and 10, more particularly SEQ ID NO: 10, and/or comprising a light chain amino acid sequence with: at least 60 percent sequence identity in the CDR regions with the CDR regions comprised in SEQ ID NO: 1, 3, 5, 7; 9, 11, 13, 15, 17, or 19, particularly SEQ ID NOs: 3, 5, and 9, more particularly SEQ ID NO: 9, particularly at least 70 percent sequence identity, more particularly at least 80 percent sequence identity, and most particularly at least 90 percent sequence identity, and/or at least 80 percent sequence homology, more particularly at least 90 percent sequence homology, most particularly at least 95 percent sequence homology in the CDR regions with the CDR regions comprised in SEQ ID NO: 1, 3, 5, 7; 9, 11, 13, 15, 17, or 19, particularly SEQ ID NOs: 3, 5, and 9, more particularly SEQ ID NO: 9. Methods for the determination of sequence homologies, for example by using a homology search matrix such as BLOSUM (Henikoff, S. & Henikoff, J. G. (1992). Amino acid substitution matrices from protein blocks. Proc. Natl. Acad. Sci. USA 89, 10915-10919), and methods for the grouping of sequences according to homologies are well known to one of ordinary skill in the art.
In particular embodiments, such a variant comprises a VL sequence comprising the set of CDR1, CDR2 and CDR3 sequences according to the VL sequence of SEQ ID NO: 19, and/or a VH sequence comprising the set of CDR1, CDR2 and CDR3 sequences according to the VH sequence of SEQ ID NO: 20, wherein in each case one of the indicated amino acid residues shown at every degenerate position “X” in SEQ ID NO: 19 and/or 20 is selected. For example, in the case of each of the positions shown as “X(S/N)” in the CDR1 of SEQ ID NO: 19, any such variant comprises either amino acid residue “S” or amino acid residue “N” at the corresponding positions.
In particular other embodiments, such a variant comprises a VL sequence according to the sequence of SEQ ID NO: 19, and/or a VH sequence according to the sequence of SEQ ID NO: 20, wherein in each case one of the indicated amino acid residues shown at every degenerate position “X” in SEQ ID NO: 19 and/or 20 is selected. For example, in the case of the position shown as “X(P/A)” in framework 1 of SEQ ID NO: 19, any such variant comprises either amino acid residue “P” or amino acid residue “A” at that position.
In particular embodiments, said antibody or functional fragment thereof comprises an antigen-binding region which is obtained by humanizing an antigen-binding region of Sections [0097] to [0099], and [00102] to [00104].
In the context of the present invention, said target-binding moiety; and said binding molecule of said multispecific molecule are not structurally limited so long as they specifically bind to said target and the binding partner of said binding molecule. However, said target-binding moiety; and said binding molecule generally consist of or are formed of one or more oligo- or polypeptides or parts thereof. Particularly, said target-binding moiety; and said binding molecule are antibody-based binding moieties, which typically comprise at least one antibody variable domain or binding fragment thereof.
In particular embodiments of the present invention, said target-binding moiety; and/or said binding molecule are/is an antibody-based binding moieties/moiety, particularly an antibody-based binding moiety comprising a heavy chain variable domain (VH) or binding fragment thereof, more particularly an antibody-based binding moiety comprising a heavy chain variable domain (VH) or binding fragment thereof and a light chain variable domain (VL) or binding fragment thereof. The term “binding fragment”, as used herein, refers to a portion of a given domain, region or part, which is (either alone or in combination with another domain, region or part thereof) still functional, i.e. capable of binding to the first or second antigen recognized by the multispecific construct.
In particular embodiments, the multispecific molecule is an antibody format selected from the group consisting of a single-chain diabody (scDb), a tandem scDb (Tandab), a linear dimeric scDb (LD-scDb), a circular dimeric scDb (CD-scDb), a bispecific T-cell engager (BiTE; tandem di-scFv), a disulfide-stabilized Fv fragment (Brinkmann et al., Proc Natl Acad Sci USA. 1993; 90: 7538-7542), a tandem tri-scFv, a tribody, bispecific Fab2, di-miniantibody, tetrabody, scFv-Fc-scFv fusion, di-diabody, DVD-Ig, IgG-scFab, scFab-dsscFv, Fv2-Fc, IgG-scFv fusions, such as bsAb (scFv linked to C-terminus of light chain), Bs1Ab (scFv linked to N-terminus of light chain), Bs2Ab (scFv linked to N-terminus of heavy chain), Bs3Ab (scFv linked to C-terminus of heavy chain), Ts1Ab (scFv linked to N-terminus of both heavy chain and light chain), Ts2Ab (dsscFv linked to C-terminus of heavy chain), and Knob-into-Holes (KiHs) (bispecific IgGs prepared by the KiH technology) and DuoBodies (bispecific IgGs prepared by the DuoBody technology), a VH and a VL domain, each fused to one C-terminus of the two different heavy chains of a KiHs or DuoBody such that one functional Fv domain is formed, Particularly suitable for use herein is a single-chain diabody (scDb), in particular a bispecific monomeric scDb. For reviews discussing and presenting various multispecific constructs see, for example, Chan Carter, Nature Reviews Immunology 10 (2010) 301-316; Schubert et al., Antibodies 1 (2012) 2-18; Byrne et al., Trends in Biotechnology 31 (2013) 621; Metz et al., Protein Engineering Design & Selection. 2012; 25:571-580).
In a particular embodiment of the present invention, the VH domain of the first and second antibody-based binding moieties of the multispecific molecule comprises rabbit heavy chain complementarity determining regions (CDRs) grafted onto human heavy chain framework (FW) regions, and the VL domain of the first and second antibody-based binding moieties of the multispecific molecule comprises rabbit light chain CDRs grafted onto human light chain FW regions.
The heavy chain and light chain CDRs of the first antibody-based binding moiety are particularly derived from a rabbit antibody obtained by immunization of a rabbit with the full-length epsilon chain of human CD3 the full-length. The immunization with the full-length chain of CD3E is suitably conducted by DNA immunization of a rabbit with a plasmid encoding the full-length chain of human CD3E, or, alternatively, with the purified extracellular domain of the epsilon chain of CD3. Further, the heavy chain and light chain CDRs of the second antibody-based binding moiety are particularly derived from a rabbit antibody obtained by immunization of a rabbit with the purified target protein or with a plasmid expressing said target.
The multispecific constructs of the present invention can be produced using any convenient antibody manufacturing method known in the art (see, e.g., Fischer, N. & Leger, O., Pathobiology 74:3-14 (2007) with regard to the production of multispecific constructs; and Hornig, N. & Färber-Schwarz, A., Methods Mol. Biol. 907:713-727, 2012 with regard to bispecific diabodies and tandem scFvs). Specific examples of suitable methods for the preparation of the multispecific construct of the present invention further include, inter alia, the Genmab (Labrijn et al., Proc Natl Acad Sci USA. 2013 Mar. 26; 110(13):5145-50) and Merus (de Kruif et al., Biotechnol Bioeng. 2010 Aug. 1; 106(5):741-50) technologies. Methods for production of multispecific antibodies comprising a functional antibody Fc part are also known in the art (see, e.g., Zhu et al., Cancer Lett. 86:127-134 (1994)); Suresh et al., Methods Enzymol. 121:210-228 (1986)).
These methods typically involve the generation of monoclonal antibodies, for example by means of fusing myeloma cells with the spleen cells from a mouse that has been immunized with the desired antigen using the hybridoma technology (see, e.g., Yokoyama et al., Curr. Protoc. Immunol. Chapter 2, Unit 2.5, 2006) or by means of recombinant antibody engineering (repertoire cloning or phage display/yeast display) (see, e.g., Chames & Baty, FEMS Microbiol. Letters 189:1-8 (2000)), and the combination of the antigen-binding domains or fragments or parts thereof of two different monoclonal antibodies to give a multispecific construct using known molecular cloning techniques.
The multispecific constructs of the present invention are particularly humanized in order to reduce immunogenicity and/or to improve stability. Techniques for humanization of antibodies are well-known in the art. For example, one technique is based on the grafting of complementarity determining regions (CDRs) of a xenogeneic antibody onto the variable light chain VL and variable heavy chain VH of a human acceptor framework (see, e.g., Jones et al., Nature 321:522-525 (1986); and Verhoeyen et al., Science 239:1534-1536 (1988)). In another technique, the framework of a xenogeneic antibody is mutated towards a human framework. In both cases, the retention of the functionality of the antigen-binding portions is essential (Kabat et al., J. Immunol. 147:1709-1719 (1991)).
In particular embodiments, said multispecific molecule is a bispecific scDb comprising two variable heavy chain domains (VH) or fragments thereof and two variable light chain domains (VL) or fragments thereof connected by linkers L1, L2 and L3 in the order VHA-L1-VLB-L2-VHB-L3-VLA, VHA-L1-VHB-L2-VLB-L3-VLA, VLA-L1-VLB-L2-VHB-L3-VHA, VLA-L1-VHB-L2-VLB-L3-VHA, VHB-L1-VLA-L2-VHA-L3-VLB, VHB-L1-VHA-L2-VLA-L3-VLB, VLB-L1-VLA-L2-VHA-L3-VHB or VLB-L1-VHA-L2-VLA-L3-VHB, particularly VLB-L1-VHA-L2-VLA-L3-VHB, wherein the VLA and VHA domains jointly form the antigen binding site for the first antigen, and VLB and VHB jointly form the antigen binding site for the second antigen, particularly wherein linker L1 is a peptide of 2-10 amino acids, particularly 3-7 amino acids, particularly 5 amino acids, particularly GGGGS, linker L3 is a peptide of 1-10 amino acids, particularly 2-7 amino acids, particularly 5 amino acids, particularly GGGGS, and the linker L2 is a peptide of 10-40 amino acids, particularly 15 to 30 amino acids, particularly 20 to 25 amino acids, particularly 20 amino acids, particularly (GGGGS)4.
The multispecific molecule of the present invention may alternatively comprise one or more binding moieties based on non-antibody based binding domains. Specific examples of suitable methods for the preparation of the multispecific construct of the present invention further include, inter alia, the DARPin technology (Molecular Partners AG), the adnexin technology (Adnexus), the anticalin technology (Pieris), and the Fynomer technology (Covagen AG).
In a third aspect, the present invention relates to a multispecific molecule comprising at least (i) a target-binding moiety; and (ii) a binding molecule, which is a binding molecule, particularly an antibody or a functional fragment thereof, binding to essentially the same epitope as the antibody or functional fragment thereof of Sections [0097] to [0099], [00102] to [00104] and [00108].
In particular embodiments, said antibody or functional fragment thereof is cross-reactive with cynomolgus CD3, particularly cynomolgus CD3ε, particularly having an affinity to cynomolgus monkey CD3ε that is less than 100-fold, particularly less than 30-fold, even more particularly less than 15-fold and most particularly less than 5-fold different to that of human CD3ε.
In a fourth aspect, the present invention relates to a pharmaceutical composition comprising a multispecific molecule of the present invention, in particular a multispecific antibody or a functional multispecific fragment thereof, and optionally a pharmaceutically acceptable carrier and/or excipient.
In a fifth aspect, the present invention relates to a nucleic acid sequence or a collection of nucleic acid sequences encoding a multispecific molecule of the present invention, in particular a bispecific antibody or a functional bispecific fragment thereof.
In a sixth aspect, the present invention relates to a vector or a collection of vectors comprising the nucleic acid sequence or a collection of nucleic acid sequences of the present invention.
In a seventh aspect, the present invention relates to a host cell, particularly an expression host cell, comprising the nucleic acid sequence or the collection of nucleic acid sequences of the present invention, or the vector or collection of vectors of the present invention.
In an eighth aspect, the present invention relates to a method for producing a multispecific molecule of the present invention, in particular an bispecific antibody or a functional bispecific fragment thereof, comprising the step of expressing the nucleic acid sequence or the collection of nucleic acid sequences of the present invention, or the vector or collection of vectors of the present invention, or the host cell, particularly an expression host cell, of the present invention.
In a ninth aspect, the present invention relates to a method for generating a multispecific molecule in accordance with the present invention comprising a CD3ε-binding antibody or a functional fragment thereof, comprising the steps of:
In a tenth aspect, the present invention relates to a multispecific molecule of the present invention for use in the treatment of a disease selected from cancer, an inflammatory disease, a metabolic disease, a cardiovascular disease, an autoimmune disease, an infectious disease, a neurologic disease, a neurodegenerative disease.
In an eleventh aspect, the present invention relates to a method of treating a disease selected from cancer, an inflammatory disease, a metabolic disease, a cardiovascular disease, an autoimmune disease, an infectious disease, a neurologic disease, a neurodegenerative disease, comprising the step of administering a multispecific molecule of the present invention to a patient in need thereof.
The following examples illustrate the invention without limiting its scope.
The approach used for the invention described herein is a step-wise procedure to increase the probability of success to identify T cell stimulatory antibodies. This approach encompasses the following procedure:
Rabbit memory B cells binding to CD3ε were isolated from one immunized rabbit using fluorescence activated cell sorting. In order to exclude antibodies binding to the interface of CD3ε and CD3γ, a Phycoerythrin (PE)-labeled single-chain protein construct was used consisting of the extracellular domains of CD3ε and CD3γ joined by a flexible peptide linker (scCD3γε). In total, 4,270 memory B cells binding to PE-scCD3γε were individually sorted into 96-well culture plates and cultured at conditions published elsewhere (Lightwood et al, JIM 2006; 316: 133-143). All culture supernatants were first screened by ELISA for binding to scCD3γε, which yielded 441 hits. In a second screening, positive supernatants from the first screening were tested for their ability to bind the native CD3ε embedded in the TCR complex on the surface of Jurkat cells (see Methods below). A total of 22 hits showed binding to CD3ε expressing Jurkat cells but not to cd3−/− Jurkat cells. The affinity to the purified extracellular domain of heterodimeric CD3εγ from human and cynomolgus monkey origin was measured using SPR for the 22 hits. Affinities to human CD3εγ as expressed by KD ranged from 0.16 to 9.28 nM (data not shown). One of the screening hits did not show binding by SPR and was therefore not considered for further analysis.
The DNA sequence encoding the variable domains of the remaining 21 clones were retrieved by RT-PCR and DNA sequencing and resulted in 18 independent clones. These rabbit IgGs were recombinantly produced in a mammalian expression system and were characterized in terms of affinity to scCD3γε from human and cynomolgus origin and their ability to bind to Jurkat cells. Phylogenetic sequence analysis of these 18 sequences revealed two main clusters, which clearly differed from each other, while there was significant homology within the two clusters (
Jurkat human T cells and cynomolgus monkey HSC-F T cells were incubated with increasing concentrations of the purified monoclonal rabbit antibodies, as described in the methods section. With all antibodies tested, specific binding to human CD3ε increased with increasing antibody concentrations (
2.23 × 10−9M
The potential of purified monoclonal rabbit anti-CD3 antibodies to induce T-cell activation as assessed by measurement of CD69 expression (see methods) was compared to the published antibodies OKT-3 and TR66. In the first approach, three different concentrations of cross-linked antibodies were used to stimulate Jurkat cells and CD69 expression was assessed by flow-cytometry 24 h later. A significant increase in CD69 expression was observed with all tested antibodies at 1.25 μg/ml (
In the second approach, T-cell activation after different time points of stimulation by anti-CD3 antibodies was analyzed. Jurkat cells were stimulated by cross-linked antibodies and CD69 expression was assessed as described above after 0, 4, 15, 24, 48 and 72 h (
In order to show the benefit of the agonistic anti-CD3 antibodies, a set of bispecific anti-CD3×IL5R single-chain diabodies (scDbs) were constructed by standard methods (methods/data not shown; Construct 1=comprises the humanized variable domain of clone-06; Construct 2=comprises the humanized variable domain of clone-02; Construct 3=comprises the humanized variable domain of clone-03).
Jurkat T cells and IL5R-expressing CHO cells (CHO-IL5R) are incubated with 1 μg/ml and 10 μg/ml of the scDbs, as described in the methods section. With all scDbs tested, specific binding to CD3ε and IL5R expressing cell lines but no unspecific binding to control cell lines is detected. The three different scDbs (Constructs 1 to 3) containing the identical anti-IL5R moiety while the anti-CD3 moieties being different, were tested for specific binding to cells expressing either IL5R or CD3ε. The anti-CD3 parts bind to overlapping epitopes with variable affinities though (Table 1 and 3 and
The potential of scDbs bound to a target cell to induce T-cell activation can be assessed by measurement of IL-2 secretion (see methods) by cytotoxic T-cells purified from human blood. The different scDbs are incubated with CD8+ cytotoxic T-cells in presence of target expressing CHO-IL5R cells at an effector:target cell ratio of 10:1 and IL-2 secretion is analyzed after 16 hours of incubation. A dose-dependent stimulation of IL-2 secretion is observed in presence of CHO-IL5R cells while essentially no IL-2 secretion is observed in presence of wild-type CHO cells (see representative data in Table 3 and in
Specific lysis of target cells by cytotoxic T-cells mediated by anti-CD3×IL5R scDbs is analyzed with the CellTox™ green cytotoxicity assay (see methods) after 88 hours of incubation. Similarly to results discussed above for T-cell activation, a dose-dependent target cell lysis is observed for Construct 1 and Construct 2 in presence of CHO-IL5R cells while no lysis is observed in presence of wild-type CHO cells (see representative data for constructs 1 to 3 in Table 3 and in
Epitope mapping and fine-mapping were performed essentially as described (Timmerman et al., Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS™ technology. J. Mol. Recognit. 20 (2007) 283-99; Slootstra et al., Structural aspects of antibody antigen interaction revealed through small random peptide libraries, Molecular Diversity 1: 87 (1996) 96). In brief, CLIPS technology structurally fixes peptides into defined three-dimensional structures. This results in functional mimics of even the most complex binding sites. CLIPS technology is now routinely used to shape peptide libraries into single, double or triple looped structures as well as sheet and helix-like folds.
CLIPS library screening starts with the conversion of the target protein into a library of up to 10,000 overlapping peptide constructs, using a combinatorial matrix design. On a solid carrier, a matrix of linear peptides is synthesized, which are subsequently shaped into spatially defined CLIPS constructs. Constructs representing both parts of the discontinuous epitope in the correct conformation bind the antibody with high affinity, which is detected and quantified. Constructs presenting the incomplete epitope bind the antibody with lower affinity, whereas constructs not containing the epitope do not bind at all. Affinity information is used in iterative screens to define the sequence and conformation of epitopes in detail.
The following clones were analyzed: clone-02, clone-03, clone-04, clone-06, and clone-10. The following target sequences of CD3 (N-terminal sequences) were used
CLUSTAL 2.1 multiple sequence alignment:
To reconstruct discontinuous epitopes of the target molecule a library of structured peptides was synthesized. This was done using the so-called “Chemically Linked Peptides on Scaffolds” (CLIPS) technology. CLIPS technology allows structuring peptides into single loops, double loops, triple loops, sheet like folds, helix like folds and combinations thereof. CLIPS templates are coupled to cysteine residues. The side chains of multiple cysteines in the peptides are coupled to one or two CLIPS templates. For example, a 0.5 mM solution of the T2 CLIPS template 1,3 bis (bromomethyl) benzene is dissolved in ammonium bicarbonate (20 mM, pH 7.9)/acetonitrile (1:1 (v/v). This solution is added onto the peptide arrays. The CLIPS template will bind to side chains of two cysteines as present in the solid phase bound peptides of the peptide arrays (455 wells plate with 3 μl wells). The peptide arrays are gently shaken in the solution for 30 to 60 minutes while completely covered in solution. Finally, the peptide arrays are washed extensively with excess of H2O and sonicated in disrupt buffer containing 1 percent SDS/0.1 percent beta mercaptoethanol in PBS (pH 7.2) at 70° C. for 30 min, followed by sonication in H2O for another 45 min. The T3 CLIPS carrying peptides were made in a similar way but now with three cysteines.
The binding of antibody to each of arrays were incubated with primary antibody solution (overnight at 4° C.). After washing, the peptide arrays were incubated with a 1/1000 dilution of an antibody peroxidase conjugate (SBA, cat. nr. 2010 05) for one hour at 25° C. After washing, the peroxidase substrate 2,2′ azino di 3 ethylbenzthiazoline sulfonate (ABTS) and 2 μl/ml of 3% H2O2 were added. After one hour, the color development was measured. The color development was quantified with a charge coupled device (CCD) camera and an image processing system.
Chemically synthesized CLIPS peptides were synthesized as described above according to the following designs.
Mimic Type Linear peptides: Double sets of linear peptides for both human and cynomolgus sequences. Length is 15 residues with an overlap of 14. Two of the sets feature a double alanine mutation (shown in grey).
Mimic Type Linear peptides with added charges
Description Control sets with added charges that are required for some antibodies that strongly interact with the peptide array surface
Mimic Type Conformational peptides
Description Peptide sequence are similar to Set 1, but are constrained into a CLIPS conformational loop.
Mimic Type CLIPS conformational peptides
Description Overlapping set of 20mer CLIPS conformational peptides
Mimic Type CLIPS discontinuous matrix peptides
Description Combinatorial set of 13mer peptides, constrained pairwise into a double looped CLIPS structure. Human and Cynomolgus peptides are ordered according to pairwise alignment to minimize technical variation.
In general, all five antibodies showed very similar binding characteristics. All binding took place on the N terminus of human CDD3ε (data not shown). Considering the binding strength and observations from constrained and non-constrained peptides, it is most likely that all antibodies bind predominantly to linear epitopes as:
Binding was observed only to N-terminal sequences
Loss of D2 or G3 does not strongly reduce binding
Loss of 2DGN4 completely abolishes binding.
The analysis identified binding regions for all five antibodies tested. All antibodies were found to bind to a seemingly linear epitope on the N terminus. All antibodies were found to bind to a similar epitope that relied strongly on 2DGN4 for binding.
15mer linear arrays derived from human and cynomolgus CD3ε, residues 2-16 and 5-20, in which each position is substituted by 18 amino acids (all natural amino acids except cysteine) were probed with the antibodies and specificities affecting the binding were found.
All antibodies bind the N terminus with an absolute requirement for N4 and an involvement of E6, and share significant similarities. All antibodies bind both human and cynomolgus versions of CD3ε, despite the small differences in sequence adjacent to the core epitope.
The initial mapping identified a linear stretch on the N terminus of CD3ε as the core epitope for all antibodies tested. Residues 2-20 of the sequences below were used to design full substitution libraries of linear 15mer peptides.
Linear peptides were synthesized by standard Fmoc synthesis on to the hydrogel of a Hi-Sense surface. After deprotection and washing, the cards were extensively washed in a sonication bath with a proprietary washing buffer.
The binding of the antibodies to each of the synthesized peptides was tested by ELISA. The peptide arrays were incubated with primary antibody solution (overnight at 4° C.). After washing, the peptide arrays were incubated with a 1/1000 dilution of an antibody peroxidase conjugate (SBA, cat. nr. 2010-05) for one hour at 25° C. After washing, the peroxidase substrate 2,2′-azino-di-3-ethylbenzthiazoline sulfonate (ABTS) and 2 μl/ml of 3% H2O2 were added. After one hour, the color development was measured. The color development was quantified with a charge coupled device (CCD)—camera and an image processing system.
Chemically synthesized CLIPS peptides were synthesized (see also Methods section) according to the following designs.
Linear peptides
Linear 15mer peptides derived from human CD3ε residues 2-16. In each peptide one of the residues is replaced by all naturally occurring amino acids (except cysteine), creating a saturation mutagenesis library.
Mimic Type: Linear peptides
Linear 15mer peptides derived from cynomolgus CD3ε residues 2-16. In each peptide one of the residues is replaced by all naturally occurring amino acids (except cysteine), creating a saturation mutagenesis library.
Mimic Type: Linear peptides
Linear 15mer peptides derived from human CD3ε residues 5-20. In each peptide one of the residues is replaced by all naturally occurring amino acids (except cysteine), creating a saturation mutagenesis library.
Linear peptides
Linear 15mer peptides derived from cynomolgus CD3ε residues 5-20. In each peptide one of the residues is replaced by all naturally occurring amino acids (except cysteine), creating a saturation mutagenesis library.
All five antibodies bind to linear peptides derived from the human and cynomolgus variant of the CD3ε N terminus in a very similar fashion, by absolutely requiring N4 (only to be supplanted by Histidine), and with a great preference for E6, for which limited substitutions are tolerated, however it seems that Glutamate is the most preferred residue at that position. None of the antibodies bound to peptides spanning residues 5-20. Within this group of five, three antibodies (Clone 2, Clone 3, and Clone 4) are more sensitive to mutations in the Cyno sequence than the other two (Clone 6, and Clone 10), in that the former group of three also is more sensitive to replacements of G3, E5, and/or G8. This observation is in line with the difference in affinity for the human and cynomolgus forms of the protein as determined by SPR (see Table 1).
The analysis fine mapped the epitopes of the five antibodies, which bind the N terminus with an absolute requirement for N4 and E6, and share significant similarities. All antibodies bind both human and cynomolgus versions of CD3ε, despite the small differences in sequence adjacent to the core epitope.
Human CD8+ T cells freshly isolated from buffy coats were incubated with CHO cells expressing human interleukin-5 receptor (hIL-5R) in an effector-to-target ratio of 10:1, with increasing concentrations of bispecific anti-IL5R×CD3ε single-chain diabodies (scDb). Both scDbs tested contained identical IL5R binding domains (VL: SEQ ID NO: 29; VH: SEQ ID NO: 30), but different CD3ε binding domains. The CD3ε binding domains tested were the variable domains of Numab's humanized clone 6 (VL: SEQ ID NO: 21; VH: SEQ ID NO: 22) and TR66 (Moore et al, Blood. 2011; 117:4542-4551). Specific lysis of target cells was assessed at various time points as described in the methods section. As depicted in
Cytokine concentrations were measured from the culture supernatants of the experiment described above. Although, showing similar potency to induce lysis of target cells, the two scDbs profoundly differed in their effects on cytokine production. While the scDb containing the variable domain of TR66 led to a steep dose-dependent increase of TNFα, there was a much reduced TNFα production observed with the scDb containing Numab's anti-CD3 domain at all effective concentrations. At 0.8 nM scDb, the lowest concentration at which the scDb containing Numab's anti-CD3 domain reached maximal target cell lysis, TNFα concentrations reached only about 50% of the concentrations produced with the scDb containing the variable domain of TR66 (
In order to explain the apparent loss of lytic potential of CD8+ T cells in presence of high concentrations of the scDb containing the variable domain of TR66 (see
The obtained sequence information of the corresponding heavy and light chain variable domains (VL and VH) was aligned and grouped according to sequence homology. The sets of rabbit variable domains were analyzed to identify unique clones and unique sets of CDRs. A combined alignment of the VL and VH domains was performed based on the joint amino acid sequences of both domains to identify unique clones. In addition to the alignment of the variable domains, the set of sequences of the six complementarity determining regions (CDRs) of each rabbit IgG clone were compared between different clones to identify unique sets of CDRs. These unique CDR sets were aligned using the multiple alignment tool COBALT and a phylogenetic tree was generated with the Neighbor Joining algorithm. The CDR sets were grouped based on sequence homology of the joined CDR sequences of each clone and a cluster threshold was determined based on sequence homology and identity. Based on the screening assay results and the cluster affiliation of the individual rabbit IgG clones candidates are selected for further analysis. Clones from different clusters were selected with the aim to proceed with high sequence diversity.
The rabbit IgG variable domains were cloned by RT-PCR amplification and ligation into a suitable mammalian expression vector for transient heterologous expression containing a leader sequence and the respective constant domains e.g. the pFUSE-rIgG vectors (Invivogen). The transient expression of the functional rlgG was performed by co-transfection of vectors encoding the heavy and light chains with the FreeStyle™ MAX system in CHO S cells. After cultivation for several days the supernatant of the antibody secreting cells was recovered for purification. Subsequently the secreted rabbit IgGs were affinity purified by magnetic Protein A beads (GE Healthcare). The IgG loaded beads were washed and the purified antibodies were eluted by a pH shift. The elution fractions were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), UV absorbance at 280 nm and size-exclusion high performance liquid chromatography (SE-HPLC) to ensure comparable quality of all samples.
The humanization of rabbit antibody clone comprised the transfer of the rabbit CDRs onto Numab's proprietary scFv acceptor framework of the Vκ1/VH3 type. In this process the amino acid sequence of the six CDR regions of a given rabbit clone was identified on the rabbit antibody donor sequence as described elsewhere (Borras, L. et al. 2010. JBC; 285:9054-9066) and grafted into the Numab acceptor scaffold sequence. In the case of rabbit clone clone-06, for example, the VL and VH sequences of the resulting humanized clone-06 are shown in SEQ ID NO: 21 and 22, respectively. Variants of the humanized light chain are shown in SEQ ID NO: 23 and 24.
Humanized IgG constructs can be made in analogy to the method described in [00165].
Binding affinities of monoclonal rabbit anti-CD3 antibodies were measured by surface plasmon resonance (SPR) using a MASS-1 SPR instrument (Sierra Sensors). For affinity measurements, an antibody specific for the Fc region of rabbit IgGs (Bethyl Laboratories, Cat. No. A120-111A) was immobilized on a sensor chip (SPR-2 Affinity Sensor, Amine, Sierra Sensors) using a standard amine-coupling procedure. Rabbit monoclonal antibodies were captured by the immobilized anti-rabbit IgG antibody. Two-fold serial dilutions of human heterodimeric single-chain CD3εγ extracellular domain (produced in-house) ranging from 90 to 2.81 nM were injected into the flow cells for 3 min and dissociation of the protein from the IgG captured on the sensor chip was allowed to proceed for 5 min. After each injection cycle, surfaces were regenerated with two injections of 10 mM glycine-HCl. The apparent dissociation (kd) and association (ka) rate constants and the apparent dissociation equilibrium constant (KD) were calculated with the MASS-1 analysis software (Analyzer, Sierra Sensors) using one-to-one Langmuir binding model.
Species cross-reactivity to cynomolgus monkey single-chain CD3εγ extracellular domain was measured using the same assay setup. Three-fold serial dilutions of cynomolgus monkey heterodimeric CD3εγ extracellular domain (produced in-house) ranging from 90 to 0.12 nM were injected into the flow cells for 3 min and dissociation of the protein from the IgG captured on the sensor chip was allowed to proceed for 5 min. After each injection cycle, surfaces were regenerated with two injections of 10 mM glycine-HCl. The apparent dissociation (kd) and association (ka) rate constants and the apparent dissociation equilibrium constant (KD) were calculated with the MASS-1 analysis software (Analyzer, Sierra Sensors) using one-to-one Langmuir binding model.
Jurkat cells (clone E6-1), a human T cell line, were seeded at 300,000 cells/well in round bottom 96-well plates in 100 μl phosphate-buffered saline (PBS) containing 10% FBS. Five-fold serial dilutions of anti-CD3 rabbit monoclonal antibodies ranging from 90 nM to 0.0058 nM were added to the plates in 100 μl PBS containing 10% FBS. Binding of rabbit antibodies to CD3ε expressed on the surface of Jurkat cells was detected by a secondary antibody specifically recognizing the Fc part of rabbit antibodies of the IgG subtype (JacksonImmuno Research, Cat. No. 111-035-046). This secondary antibody was linked to the enzyme horseradish peroxidase (HRP). HRP activity was measured by addition of TMB substrate (3,3′,5,5′-tetramethylbenzidine, KPL, Cat. No. 53-00-00), which in a colorimetric reaction is processed by the HRP. The color intensity of the processed substrate is directly proportional to the amount of anti-CD3 antibody bound to Jurkat cells. To quantify color intensity, light absorbance (optical density) at the respective wave length was measured using a microtiter plate reader (Infinity reader M200 Pro, Tecan).
To correct for unspecific binding of the antibodies to unknown components presented on the cell surface of Jurkat cells, a CD3ε deficient derivative of the Jurkat T cell line (J.RT3-T3.5) was used. Binding of the monoclonal antibodies to this cell line was measured as described above for the Jurkat cells. For quantification of specific binding to Jurkat cells, the optical density for binding to the negative control was subtracted from the optical density for binding to Jurkat cells. Data were analyzed using a four-parameter logistic curve fit using the Softmax Data Analysis Software (Molecular Devices), and the molar concentration of anti-CD3 antibody required to reach 50% binding (EC50, mid-OD of the standard curve) was derived from dose response curves.
Binding to cynomolgus monkey CD3 presented on the cell surface of HSC-F T cells was measured using the same assay setup. HSC-F cells, a cynomolgus monkey T cell line, were seeded at 300,000 cells/well in round bottom 96-well plates in 100 μl phosphate-buffered saline (PBS) containing 10% FBS. Five-fold serial dilutions of anti-CD3 rabbit monoclonal antibodies ranging from 18 nM to 0.0058 nM were added to the plates in 100 μl PBS containing 10% FBS. Binding of rabbit antibodies to cynomolgus monkey CD3ε expressed on the surface of HSC-F cells was detected by a secondary antibody specifically recognizing the Fc part of rabbit antibodies of the IgG subtype (JacksonImmuno Research, Cat. No. 111-035-046). This secondary antibody was linked to the enzyme horseradish peroxidase (HRP). HRP activity was measured as described above.
To correct for unspecific binding of the antibodies to unknown components presented on the cell surface, a CD3ε negative human B lymphoblast cell line (DB) was used. Binding of the monoclonal antibodies to this cell line was measured as described above. For quantification of specific binding to HSC-F cells, the optical density for binding to the negative control was subtracted from the optical density for binding to HSC-F cells. Data were analyzed using a four-parameter logistic curve fit using the Softmax Data Analysis Software (Molecular Devices), and the molar concentration of anti-CD3 antibody required to reach 50% binding (EC50, mid-OD of the standard curve) was derived from dose response curves.
The potential of monoclonal rabbit anti-CD3 antibodies to induce T-cell activation was evaluated by measurement of induction of CD69 expression, an early T-cell activation marker, in Jurkat cells, described elsewhere (Gil et al, Cell. 2002; 109: 901-912). For dose-response assays, Jurkat cells (100,000 cells/well) were stimulated for 24 h with 20 μg/ml, 5 μg/ml and 1.25 μg/ml of anti-CD3 antibodies. Prior to addition of anti-CD3 monoclonal antibodies to Jurkat cells, anti-CD3 antibodies were cross-linked by addition of 3-fold excess of a goat anti-rabbit IgG antibody (Bethyl Laboratories, Cat. No. A120-111A) and a rabbit anti-mouse IgG antibody (JacksonImmuno Research, Cat. No. 315-005-008) respectively when OKT3 (BioLegend, Cat. No. 317302) or TR66 (Novus Biologicals, Cat. No. NBP1-97446) were used. After stimulation, cells were stained for CD69 expression using a Phycoerithrin (PE)-labeled antibody specific for human CD69 (BioLegend, Cat. No. 310906) and then analyzed with a flow cytometer (FACS aria III, Becton Dickinson). As negative control unstimulated Jurkat cells incubated with the cross-linking antibody were stained with the anti-CD69 antibody described above. T-cell activation over time was assessed with a similar assay setup as described above. 100,000 Jurkat cells/well were stimulated for 0 h, 4 h, 15 h, 24 h, 48 h and 72 h with 5 μg/ml anti-CD3 antibodies that have been cross-linked as described above. Identical to the dose-response assay, CD69 expression was analyzed by flow cytometry.
Manufacturing of scDb Constructs
The nucleotide sequences encoding the various anti-IL5R×CDE3ε scDb constructs were de novo synthesized and cloned into an adapted vector for E. coli expression that is based on a pET26b(+) backbone (Novagen). The expression construct was transformed into the E. coli strain BL12 (DE3) (Novagen) and the cells were cultivated in 2YT medium (Sambrook, J., et al., Molecular Cloning: A Laboratory Manual) as a starting culture. Expression cultures were inoculated and incubated in shake flasks at 37° C. and 200 rpm. Once an OD600 nm of 1 was reached protein expression was induced by the addition of IPTG at a final concentration of 0.5 mM. After overnight expression the cells were harvested by centrifugation at 4000 g. For the preparation of inclusion bodies the cell pellet was resuspended in IB Resuspension Buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 5 mM EDTA, 0.5% Triton X-100). The cell slurry was supplemented with 1 mM DTT, 0.1 mg/mL Lysozyme, 10 mM Leupeptin, 100 μM PMSF and 1 μM Pepstatin. Cells are lysed by 3 cycles of ultrasonic homogenization while being cooled on ice. Subsequently 0.01 mg/mL DNAse was added and the homogenate was incubated at room temperature for 20 min. The inclusion bodies were sedimented by centrifugation at 15000 g and 4° C. The IBs were resuspended in IB resuspension Buffer and homogenized by sonication before another centrifugation. In total a minimum of 3 washing steps with IB Resuspension Buffer were performed and subsequently 2 washes with IB Wash Buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 5 mM EDTA) were performed to yield the final IBs.
For protein refolding the isolated IBs were resuspended in Solubilization Buffer (100 mM Tris/HCl pH 8.0, 6 M Gdn-HCl, 2 mM EDTA) in a ratio of 5 mL per g of wet IBs. The solubilization was incubated for 30 min at room temperature until DTT was added at a final concentration of 20 mM and the incubation was continued for another 30 min. After the solubilization was completed the solution was cleared by 10 min centrifugation at 21500 g and 4° C. The refolding was performed by rapid dilution at a final protein concentration of 0.3 g/L of the solubilized protein in Refolding Buffer (typically: 100 mM Tris-HCl pH 8.0, 5.0 M Urea, 5 mM Cysteine, 1 mM Cystine). The refolding reaction was routinely incubated for a minimum of 14 h. The resulting protein solution was cleared by 10 min centrifugation at 8500 g and 4° C. The refolded protein was purified by affinity chromatography on Capto L resin (GE Healthcare). The isolated monomer fraction was analyzed by size-exclusion HPLC, SDS-PAGE for purity and UVNis spectroscopy for protein content. Buffer was exchanged into native buffer (50 mM Citrate-Phosphate pH 6.4, 200 mM NaCl) by dialysis.
SPR Assay for Determination of Binding Kinetics of Bispecific Anti-CD3×IL5R scDbs
Binding affinities of anti-CD3×IL5R scDbs were measured by surface plasmon resonance (SPR) using a MASS-1 SPR instrument (Sierra Sensors). For affinity measurements to CD3, human heterodimeric single-chain CD3εγ extracellular domain (produced in-house) is immobilized on a sensor chip (SPR-2 Affinity Sensor High Capacity, Amine, Sierra Sensors) using a standard amine-coupling procedure. Three-fold serial dilutions of scDbs ranging from 90 to 0.1 nM were injected into the flow cells for 3 min and dissociation of the protein from the CD3εγ immobilized on the sensor chip was allowed to proceed for 12 min. After each injection cycle, surfaces are regenerated with two injections of 10 mM Glycine-HCl (pH 2.0). For affinity measurements against IL5R, an antibody specific for the Fc region of human IgGs was immobilized on a sensor chip (SPR-2 Affinity Sensor High Capacity, Amine, Sierra Sensors) by amine-coupling. A human IL5R-Fc chimeric protein (Novus Biologicals) was captured by the immobilized antibody. Three-fold serial dilutions of scDbs specific for IL5R (90 nM-0.1 nM) are injected into the flow cells for three minutes and dissociation is monitored for 12 minutes. After each injection cycle, surfaces are regenerated with three injections of 10 mM Glycine-HCl (pH 1.5). The apparent dissociation (kd) and association (ka) rate constants and the apparent dissociation equilibrium constant (KD) are calculated with the MASS-1 analysis software (Analyzer, Sierra Sensors) using one-to-one Langmuir binding model.
Binding of Bispecific Anti-CD3×IL5R scDbs to CD3ε Expressed on the Cell Surface of T-Cells and to IL5R Expressed on the Surface of CHO Cells (CHO-IL5R Cells)
Binding of scDbs to CD3ε expressed on the cell surface of Jurkat cells (clone E6-1, ATCC), a human T cell line, was analyzed by flow cytometry. To assess unspecific binding of the scDbs to unknown components presented on the cell surface of Jurkat cells a CD3ε deficient derivative of the Jurkat T cell line (J.RT3-T3.5, ATCC) was used. Binding of scDbs to IL5R expressed on the cell-surface was analyzed using transgenic CHO-IL5R cells (generated at ZHAW) and wild-type CHO cells (Invitrogen) were used as controls for unspecific binding. Both cell lines were incubated with 1 μg/mL and 10 μg/mL of scDbs for 1 hour and bound scDbs were detected by addition of RPE-labeled protein L (BioVision) and then analyzed with a flow cytometer (FACS aria III, Becton Dickinson). As negative control a scFv specific for an unrelated target was used. For the qualitative assessment of binding to Jurkat and CHO-IL5R cells the mean fluorescence intensity (MFI), reflecting the signal intensity at the geometric mean, was measured for both, the unspecific scFv as well as for the test scDbs. The difference of the MFI between test antibody and negative control antibody (ΔMFI) was calculated as a measure for binding. Furthermore, the normalized MFI was calculated by dividing the MFI of the test scDb through the MFI of the negative control scFv.
T-Cell Activation by Bispecific Anti-CD3×IL5R scDbs: Induction of IL-2 Secretion
The potential of anti-CD3×anti-IL5R scDbs to induce IL-2 expression in CD8+ cytotoxic T-cells in presence of target cells was evaluated as follows. Cytotoxic T-cells were freshly isolated from human blood by using the RosetteSep™ human CD8+ T-cell enrichment cocktail (STEMCELL Technologies) according to the manufacturer's instructions. CHO-IL5R cells (10'000 cells/well) were incubated with CD8+ cytotoxic T-cells at an effector:target ratio of 10:1 in presence of 10-fold serially diluted scDbs (100 nM to 0.001 nM) in 96 well microtiter plates. To assess unspecific stimulation of T-cells wild-type CHO cells were used as target cells. Supernatant was collected after 16 hours of co-incubation to measure IL-2 release. IL-2 release was quantified using a commercially available ELISA kit (BioLegend). Data were analyzed using a four-parameter logistic curve fit using the SoftMax® Pro data analysis Software (Molecular Devices), and the molar concentration of scDb required to induce half maximal IL-2 secretion (EC50) is derived from dose-response curves.
scDb Mediated Lysis of IL5R Expressing CHO Cells by Cytotoxic T Cells
For assessment of the potential of bispecific anti-CD3×IL5R scDbs to induce target cell lysis a transgenic IL5R expressing CHO cell line was used (CHO-IL5R). Unstimulated human CD8+ T-cells isolated as described above were used as effector cells. Target cells were labeled with cell tox green dye (Promega) according to the manufacturer's instructions. Cell lysis was monitored by the CellTox™ green cytotoxicity assay (Promega). The assay measures changes in membrane integrity that occur as a result of cell death. The assay uses an asymmetric cyanine dye that is excluded from viable cells but preferentially stains the dead cell DNA. When the dye binds DNA in compromised cells, its fluorescence properties are substantially enhanced. Viable cells produce no appreciable increases in fluorescence. Therefore, the fluorescence signal produced by the binding interaction with dead cell DNA is proportional to cytotoxicity. Similarly as described above, labeled CHO-IL5R cells (10'000 cells/well) were incubated with CD8+ cytotoxic T-cells at an effector:target ratio of 10:1 in presence of 10-fold serially diluted scDbs (100 nM to 0.001 nM) in 96 well microliter plates. To assess unspecific lysis of cells that do not express the target, T-cells were co-incubated with labeled wild-type CHO cells. Fluorescence intensity was analyzed after 88 h of incubation using a multi-mode microplate reader (FlexStation 3, Molecular Devices). Data were analyzed using a four-parameter logistic curve fit using the SoftMax® Pro data analysis Software (Molecular Devices), and the molar concentration of scDb required to induce half maximal target cell lysis (EC50) was derived from dose-response curves.
Two different single-chain diabody (scDb) constructs were engineered using well-known standard recombinant DNA techniques. Both scDbs contain identical IL5R binding variable domains (VL: SEQ ID NO: 29; VH: SEQ ID NO: 30)) but different anti-CD3 domains. The two anti-CD3 binding domains used are on one hand the humanized variable domain of clone 6 (SEQ ID NO: 21: VL; SEQ ID NO: 22: VH) and on the other hand the variable domain of the anti-CD3 antibody TR66 described elsewhere (Moore et al, Blood. 2011; 117:4542-4551).
The bispecific scDb constructs were of the following design: VLA-L1-VHB-L2-VLB-L3-VHA wherein the VLA and VHA domains jointly form the antigen binding site for human IL5R, and VLB and VHB jointly form the antigen binding site for human CD3ε. These variable domain sequence segments are linked by the flexible amino acid linkers L1 and L3 each consisting of the amino acid sequences GGGGS (G4S) and the middle linker L2 consisting of the amino acid sequence GGGGSGGGGSGGGGSGGGGS (G4S)4.
The nucleotide sequences encoding the two anti-IL5R×CDE3ε scDb constructs were de novo synthesized and cloned into an adapted vector for E. coli expression that is based on a pET26b(+) backbone (Novagen). The expression construct was transformed into the E. coli strain BL12 (DE3) (Novagen) and the cells were cultivated in 2YT medium (Sambrook, J., et al., Molecular Cloning: A Laboratory Manual) as a starting culture. Expression cultures were inoculated and incubated in shake flasks at 37° C. and 200 rpm. Once an OD600 nm of 1 was reached protein expression was induced by the addition of IPTG at a final concentration of 0.5 mM. After overnight expression the cells were harvested by centrifugation at 4000 g. For the preparation of inclusion bodies the cell pellet was resuspended in IB Resuspension Buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 5 mM EDTA, 0.5% Triton X-100). The cell slurry was supplemented with 1 mM DTT, 0.1 mg/mL Lysozyme, 10 mM Leupeptin, 100 μM PMSF and 1 μM Pepstatin. Cells are lysed by 3 cycles of ultrasonic homogenization while being cooled on ice. Subsequently 0.01 mg/mL DNAse was added and the homogenate was incubated at room temperature for 20 min. The inclusion bodies were sedimented by centrifugation at 15000 g and 4° C. The IBs were resuspended in IB resuspension Buffer and homogenized by sonication before another centrifugation. In total a minimum of 3 washing steps with IB Resuspension Buffer were performed and subsequently 2 washes with IB Wash Buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 5 mM EDTA) were performed to yield the final IBs.
For protein refolding the isolated IBs were resuspended in Solubilization Buffer (100 mM Tris/HCl pH 8.0, 6 M Gdn-HCl, 2 mM EDTA) in a ratio of 5 mL per g of wet IBs. The solubilization was incubated for 30 min at room temperature until DTT was added at a final concentration of 20 mM and the incubation was continued for another 30 min. After the solubilization was completed the solution was cleared by 10 min centrifugation at 21500 g and 4° C. The refolding was performed by rapid dilution at a final protein concentration of 0.3 g/L of the solubilized protein in Refolding Buffer (typically: 100 mM Tris-HCl pH 8.0, 5.0 M Urea, 5 mM Cysteine, 1 mM Cystine). The refolding reaction was routinely incubated for a minimum of 14 h. The resulting protein solution was cleared by 10 min centrifugation at 8500 g and 4° C. The refolded protein was purified by affinity chromatography on Capto L resin (GE Healthcare). The isolated monomer fraction was analyzed by size-exclusion HPLC, SDS-PAGE for purity and UVNis spectroscopy for protein content. Buffer was exchanged into native buffer (50 mM Citrate-Phosphate pH 6.4, 200 mM NaCl) by dialysis.
The potential of anti-IL5R×CD3 scDbs to induce cytokine expression in CD8+ cytotoxic T-cells in presence of target cells was evaluated as follows. CD8+ T-cells were freshly isolated from human blood by using the RosetteSep™ human CD8+ T-cell enrichment cocktail (STEMCELL Technologies) according to the manufacturer's instructions or from human buffy coats using the EasySep™ Human CD8+ T Cell Enrichment Kit (STEMCELL Technologies). CHO-IL5R cells (10'000 cells/well) were incubated with CD8+ cytotoxic T-cells at an effector:target ratio of 10:1 in presence of serially diluted scDbs (100, 20, 4, 0.8, 0.16, 0.032, 0.0064 nM) in 96 well microtiter plates. To assess unspecific stimulation of T-cells wild-type CHO cells were used as target cells. Supernatant was collected after 64 hours of co-incubation to measure cytokine concentrations. Cytokine release was quantified using commercially available ELISA kits (IFNγ: BioLegend; TNF:BioLegend; IL-10: BioLegend; TGFβ: BioLegend; IL-6: BioLegend). Data were analyzed using a four-parameter logistic curve fit using the SoftMax Pro data analysis Software (Molecular Devices).
The potential of bispecific anti-IL5R×CD3 scDbs to induce T-cell activation was evaluated by measurement of induction of CD69 expression, an early T-cell activation marker, described elsewhere (Gil et al, Cell. 2002; 109: 901-912). After 18 hours, cells were stained for CD69 expression using a Phycoerithrin (PE)-labeled antibody specific for human CD69 (BioLegend, Cat. No. 310906) and then analyzed with a flow cytometer (NovoCyte, Acea Biosciences). As negative control unstimulated human CD8+ T cells were incubated with hIL5R negative CHO cells at the same conditions as described above.
Similar results can be obtained by using analogous procedures for other exhaustion markers, such as TIM-3, PD-1, CTLA-4, CD160, CD244, or LAG-3.
For assessment of the potential of bispecific anti-IL5R×CD3 scDbs to induce target cell lysis a transgenic IL5R expressing CHO cell line was used (CHO-IL5R). Unstimulated human CD8+ T-cells isolated as described above were used as effector cells. Target cells were labeled with cell tox green dye (Promega) according to the manufacturer's instructions. Cell lysis was monitored by the CellTox™ green cytotoxicity assay (Promega). The assay measures changes in membrane integrity that occur as a result of cell death. The assay uses an asymmetric cyanine dye that is excluded from viable cells but preferentially stains the dead cell DNA. When the dye binds DNA in compromised cells, its fluorescence properties are substantially enhanced. Viable cells produce no appreciable increases in fluorescence. Therefore, the fluorescence signal produced by the binding interaction with dead cell DNA is proportional to cytotoxicity. Similarly as described above, labeled CHO-IL5R cells (10'000 cells/well) were incubated with CD8+ cytotoxic T-cells at an effector:target ratio of 10:1 in presence of 5-fold serially diluted scDbs (100, 20, 4, 0.8, 0.16, 0.032, 0.0064 nM) in 96 well microtiter plates. To assess unspecific lysis of cells that do not express the target, T-cells were co-incubated with labeled wild-type CHO cells. Fluorescence intensity was analyzed after 18, 24, 40, 48 and 64 hours of incubation using a multi-mode microplate reader (FlexStation 3, Molecular Devices). Data were analyzed using a four-parameter logistic curve fit using the SoftMax Pro data analysis Software (Molecular Devices), and the molar concentration of scDb required to induce half maximal target cell lysis (EC50) was derived from dose-response curves.
NNNRLS
WFQQKPGQPPKQLIYSASSLASG
YAMI
WVRQAPGKGLEWIGMILRAGNIYYAS
WAKG
RFTISKTSTTVDLKITSPTTEDTATYF
[CDR1 to 3 shown in bold and underlined in SEQ ID NOs: 1 and 2 as representatives for all sequences]
[in SEQ ID NOs: 19 and 20: positions “X” are degenerate positions: respective degeneracy provided in square brackets behind individual “X”]
The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.
To the extent possible under the respective patent law, all patents, applications, publications, test methods, literature, and other materials cited herein are hereby incorporated by reference.
| Number | Date | Country | Kind |
|---|---|---|---|
| PCT/EP2014/001282 | May 2014 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2014/002937 | 11/3/2014 | WO | 00 |
